## Decreased Prevalence of Alzheimer Disease Associated Coenzyme A Reductase Inhibitors

Archives of Neurology 57, 1439 DOI: 10.1001/archneur.57.10.1439

**Citation Report** 

#	Article	IF	CITATIONS
2	Is There a Connection Between the Concentration of Cholesterol Circulating in Plasma and the Rate of Neuritic Plaque Formation in Alzheimer Disease?. Archives of Neurology, 2000, 57, 1410.	4.5	81
3	Statins and the risk of dementia. Lancet, The, 2000, 356, 1627-1631.	13.7	1,677
4	Use of statins in CNS disorders. Journal of the Neurological Sciences, 2001, 187, 81-89.	0.6	116
5	A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Neurobiology of Disease, 2001, 8, 890-899.	4.4	505
6	Mutations in the 3Î <sup>2</sup> -Hydroxysterol Δ24-Reductase Gene Cause Desmosterolosis, an Autosomal Recessive Disorder of Cholesterol Biosynthesis. American Journal of Human Genetics, 2001, 69, 685-694.	6.2	318
7	Cholesterol, Al² and Alzheimer's disease. Trends in Neurosciences, 2001, 24, S45-S48.	8.6	88
8	Cholesterol, A $\hat{I}^2$ and Alzheimer's disease. Trends in Neurosciences, 2001, 24, 45-48.	8.6	65
9	Do Statins Afford Neuroprotection in Patients with Cerebral Ischaemia and Stroke?. CNS Drugs, 2001, 15, 589-596.	5.9	30
10	Medication Use in Alzheimer's Disease and Healthy Aging. Clinical Gerontologist, 2001, 24, 75-84.	2.2	0
11	Joint Effect of the <i>APOE</i> Gene and Midlife Systolic Blood Pressure on Late-Life Cognitive Impairment. Stroke, 2001, 32, 2882-2889.	2.0	126
12	Therapeutic targets in the biology of Alzheimer's disease. Current Opinion in Psychiatry, 2001, 14, 341-348.	6.3	14
13	Current theories for the molecular and cellular pathogenesis of Alzheimer's disease. Expert Reviews in Molecular Medicine, 2001, 3, 1-11.	3.9	6
14	Issues surrounding age: vascular disease in the elderly. Current Opinion in Lipidology, 2001, 12, 601-609.	2.7	29
15	Cholesterol metabolism in the brain. Current Opinion in Lipidology, 2001, 12, 105-112.	2.7	775
16	Community studies of psychogeriatric disorders. Current Opinion in Psychiatry, 2001, 14, 383-386.	6.3	3
17	Progress in the modeling of neurodegenerative diseases in transgenic mice. Current Opinion in Neurology, 2001, 14, 441-447.	3.6	21
18	Statins for the prevention of Alzheimer's disease and dementia. , 2001, , CD003160.		56
19	Drug treatment in dementia. Current Opinion in Psychiatry, 2001, 14, 349-353.	6.3	11

ARTICLE IF CITATIONS # Differential effects of lovastatin treatment on brain cholesterol levels in normal and ApoE-deficient 20 1.2 70 mice. NeuroReport, 2001, 12, 883-887. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain. NeuroReport, 1.2 2001, 12, 2935-2938. Alzheimer Disease Therapeutics. Journal of Neuropathology and Experimental Neurology, 2001, 60, 22 1.7 42 923-928. Alzheimer's disease: molecular concepts and therapeutic targets. Die Naturwissenschaften, 2001, 88, 261-267. Statins and blood pressure regulation. Current Hypertension Reports, 2001, 3, 281-288. 26 3.5 49 Pharmacotheraphy for Alzheimer's disease. Current Neurology and Neuroscience Reports, 2001, 1, 4.2 428-434. Serum Cholesterol and Cerebrospinal Fluid Amyloid ÃŽÂ<sup>2</sup> Protein in Alzheimer'S Disease. Journal of the 28 2.6 8 American Geriatrics Society, 2001, 49, 1738-1739. Folate Deficiency and Risk of Pneumonia in Older People. Journal of the American Geriatrics Society, 2.6 40 2001, 49, 1739-1741. Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. Cellular and Molecular 31 3.3 29 Neurobiology, 2001, 21, 299-315. Concentrations of different sterols in the striatum and serum of 3-nitropropionic acid-treated 3.3 Wistar and Lewis rats. Neurochemical Research, 2001, 26, 1237-1244. Emerging perspectives on lipid management: international approaches and global challenges. American 33 2 1.6 Journal of Cardiology, 2001, 88, 876-881. Compartmentalization of  $\hat{l}^2$ -secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Current 300 Biology, 2001, 11, 1288-1293. Amyloid-Î<sup>2</sup>: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. 35 2.9 155 Free Radical Biology and Medicine, 2001, 31, 1120-1131. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug 6.4 Discovery Today, 2001, 6, 1049-1055 Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's 37 6.4 31 disease. Drug Discovery Today, 2001, 6, 1207-1219. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. Journal of Cellular and Molecular Medicine, 2001, 5, 254-266. 101 A fluid connection: Cholesterol and AÎ<sup>2</sup>. Proceedings of the National Academy of Sciences of the United 39 7.1 187 States of America, 2001, 98, 5371-5373. Experimental approaches and drugs in development for the treatment of dementia. Expert Opinion on 4.1 Investigational Drugs, 2001, 10, 607-617.

#	Article	IF	CITATIONS
41	Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptide. International Journal of Neuropsychopharmacology, 2001, 4, 127-30.	2.1	87
42	Nutritional Factors and Alzheimer's Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2001, 56, M675-M680.	3.6	49
43	Dementia at old age: a clinical end-point of atherosclerotic disease. European Heart Journal Supplements, 2001, 3, N16-N19.	0.1	11
44	Is sticky blood a treatable determinant of cognitive decline and of dementia?. Age and Ageing, 2001, 30, 101-103.	1.6	17
45	Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 <i>in vitro</i> and <i>in vivo</i> . Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5856-5861.	7.1	1,050
46	Cholesterol and Alzheimer's disease. Neurology, 2001, 57, 1089-1093.	1.1	260
47	Statins and neuroprotection. Expert Opinion on Investigational Drugs, 2001, 10, 1847-1853.	4.1	29
48	Statins and the Acute-Phase Response. New England Journal of Medicine, 2001, 344, 2016-2018.	27.0	144
49	New concepts in the drug therapy of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2001, 2, 1975-1983.	1.8	6
50	Bone growth stimulators New tools for treating bone loss and mending fractures. Vitamins and Hormones, 2002, 65, 1-80.	1.7	14
51	Induction of the Cholesterol Transporter ABCA1 in Central Nervous System Cells by Liver X Receptor Agonists Increases Secreted Al² Levels. Journal of Biological Chemistry, 2002, 277, 48508-48513.	3.4	139
52	Metalloenzyme-like Activity of Alzheimer's Disease β-Amyloid. Journal of Biological Chemistry, 2002, 277, 40302-40308.	3.4	536
53	Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly People. Archives of Neurology, 2002, 59, 223.	4.5	495
54	Function of βâ€amyloid in cholesterol transport: a lead to neurotoxicity. FASEB Journal, 2002, 16, 1677-1679.	0.5	109
55	Reduction of Plasma 24S-Hydroxycholesterol (Cerebrosterol) Levels Using High-Dosage Simvastatin in Patients With Hypercholesterolemia. Archives of Neurology, 2002, 59, 213.	4.5	154
56	Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women. Archives of Neurology, 2002, 59, 378.	4.5	420
57	Alzheimer Disease. JAMA - Journal of the American Medical Association, 2002, 287, 2335.	7.4	379
58	Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Report, 2002, 7, 199-206.	4.5	167

#	Article	IF	CITATIONS
59	The cerebellum may be directly involved in cognitive functions. Neurology, 2002, 59, 790-791.	1.1	13
60	No Association of Paraoxonase Genotype or Atherosclerosis With Cerebral Amyloid Angiopathy. Stroke, 2002, 33, 896-900.	2.0	13
61	Alzheimers Disease: An Overview of Current and Emerging Therapeutic Strategies. Current Topics in Medicinal Chemistry, 2002, 2, 343-352.	2.1	28
62	Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond. Current Medicinal Chemistry, 2002, 9, 1831-1850.	2.4	54
63	Diet and risk of dementia: Does fat matter?. Neurology, 2002, 59, 1915-1921.	1.1	280
64	Einsatz der Statine in der Neurologie. Aktuelle Neurologie, 2002, 29, 254-261.	0.1	4
65	Apolipoprotein E (ApoE) Isoform-dependent Lipid Release from Astrocytes Prepared from Human ApoE3 and ApoE4 Knock-in Mice. Journal of Biological Chemistry, 2002, 277, 29919-29926.	3.4	183
66	Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Neurology, 2002, 59, 787-787.	1.1	9
67	Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence. Epidemiologic Reviews, 2002, 24, 248-268.	3.5	56
68	Cholesterol and neuropathologic markers of AD: A population-based autopsy study. Neurology, 2002, 59, 788-789.	1.1	61
69	Will neurology residents with large student loan debts become academicians?. Neurology, 2002, 59, 789-790.	1.1	1
70	Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology, 2002, 59, 787-788.	1.1	2
71	The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M414-M418.	3.6	158
72	Do persons with dementia vote?. Neurology, 2002, 59, 149-149.	1.1	8
73	Risk Factors for Alzheimer's Disease: Role of Multiple Antioxidants, Non-Steroidal Anti-inflammatory and Cholinergic Agents Alone or in Combination in Prevention and Treatment. Journal of the American College of Nutrition, 2002, 21, 506-522.	1.8	65
74	Regulation of Cholesterol Homeostasis by the Liver X Receptors in the Central Nervous System. Molecular Endocrinology, 2002, 16, 1378-1385.	3.7	182
75	Multiple sclerosis distribution in northern Sardinia: Spatial cluster analysis of prevalence. Neurology, 2002, 59, 790-790.	1.1	0
76	Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. Journal of Lipid Research, 2002, 43, 1078-1085.	4.2	132

#	Article	IF	Citations
77	Ischemic stroke and active migraine. Neurology, 2002, 59, 149-150.	1.1	3
78	Aging and dementia: principles, evaluation and diagnosis. , 2002, , 237-251.		1
80	The significance of environmental factors in the etiology of Alzheimer's disease. Journal of Alzheimer's Disease, 2002, 4, 179-189.	2.6	187
81	Statins in the Prevention and Treatment of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2002, 16, 131-136.	1.3	80
82	Interactions between hypercholesterolemia and hypertension: implications for therapy. Current Opinion in Nephrology and Hypertension, 2002, 11, 489-496.	2.0	52
83	Cholesterol and Alzheimer's disease. Biochemical Society Transactions, 2002, 30, 525-529.	3.4	51
84	Non-familial Alzheimer's disease is mainly due to genetic factors. Journal of Alzheimer's Disease, 2002, 4, 169-177.	2.6	132
85	Chapter 20. Searching for Alzheimer's disease therapies in your medicine cabinet: The epidemiological and mechanistic case for NSAIDs and statins. Annual Reports in Medicinal Chemistry, 2002, 37, 197-208.	0.9	0
86	Recent developments: Recent developments in neurology. BMJ: British Medical Journal, 2002, 324, 656-660.	2.3	6
87	Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer??s Disease. CNS Drugs, 2002, 16, 435-444.	5.9	66
88	Alzheimer Disease as a Vascular Disorder. Stroke, 2002, 33, 1152-1162.	2.0	788
89	Cholesterol-Dependent γ-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains. Neurobiology of Disease, 2002, 9, 11-23.	4.4	406
90	Interactions of AÎ <sup>2</sup> with Endogenous Anti-Inflammatory Agents: A Basis for Chronic Neuroinflammation in Alzheimer's Disease. Neurobiology of Disease, 2002, 10, 187-200.	4.4	7
91	Pharmacodynamic activity of drugs and ecotoxicology—can the two be connected?. Toxicology Letters, 2002, 131, 105-115.	0.8	135
92	Statins inhibit Aβ-neurotoxicity in vitro and Aβ-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis, 2002, 161, 293-299.	0.8	32
93	Cholesterol attenuates the membrane perturbing properties of β-amyloid peptides. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 149-160.	3.0	29
94	The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. Science, 2002, 297, 353-356.	12.6	12,113
95	Apolipoprotein E ϵ4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease. Annals of Internal Medicine, 2002, 137, 149.	3.9	561

#	Article	IF	CITATIONS
96	Health-Related Quality of Life and Long-Term Therapy with Pravastatin and Tocopherol (Vitamin E) in Older Adults. Drugs and Aging, 2002, 19, 793-805.	2.7	33
97	Disordered proteins in dementia. Annals of Medicine, 2002, 34, 259-271.	3.8	18
98	Could statins prevent age-related macular degeneration?. Expert Opinion on Pharmacotherapy, 2002, 3, 803-807.	1.8	10
99	HYPOLIPEMIC AGENTS FOR STROKE PREVENTION. Clinical and Experimental Hypertension, 2002, 24, 573-594.	1.3	8
100	Is pharmacological prevention of Alzheimer's a realistic goal?. Expert Opinion on Pharmacotherapy, 2002, 3, 365-380.	1.8	16
101	Non-Cholinergic Strategies for Treating and Preventing Alzheimer??s Disease. CNS Drugs, 2002, 16, 811-824.	5.9	123
102	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, The, 2002, 360, 1623-1630.	13.7	3,147
103	Lipoprotein Receptors in the Nervous System. Annual Review of Biochemistry, 2002, 71, 405-434.	11.1	402
104	Liver X receptors in the central nervous system: From lipid homeostasis to neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13878-13883.	7.1	256
105	Aluminum accumulation and membrane fluidity alteration in synaptosomes isolated from rat brain cortex following aluminum ingestion: effect of cholesterol. Neuroscience Research, 2002, 44, 181-193.	1.9	42
106	Biogenesis and metabolism of Alzheimer's disease Aβ amyloid peptides. Peptides, 2002, 23, 1285-1297.	2.4	149
107	Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiology of Aging, 2002, 23, 485-508.	3.1	173
108	Biomarkers for early detection of dementia—author's response. Neurobiology of Aging, 2002, 23, 521-522.	3.1	5
109	Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiology of Aging, 2002, 23, 685-694.	3.1	139
110	Policosanol safely down-regulates HMG-CoA reductase – potential as a component of the Esselstyn regimen. Medical Hypotheses, 2002, 59, 268-279.	1.5	46
111	Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends in Pharmacological Sciences, 2002, 23, 324-330.	8.7	63
112	Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers. Neuroscience Letters, 2002, 331, 60-62.	2.1	12
113	Should Hypercholesterolemia Be Treated in Frail Elders?. Journal of the American Medical Directors Association, 2002, 3, 66-70.	2.5	1

#	Article	IF	CITATIONS
114	Inhibition of Intracellular Cholesterol Transport Alters Presenilin Localization and Amyloid Precursor Protein Processing in Neuronal Cells. Journal of Neuroscience, 2002, 22, 1679-1689.	3.6	232
115	Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer b-amyloid peptide in vitro and in patients. Frontiers in Bioscience - Landmark, 2002, 7, a50.	3.0	40
116	Maladie d'Alzheimer : vision d'ensemble, aspects cliniques, facteurs de risque et prévention. Medecine/Sciences, 2002, 18, 689-696.	0.2	0
117	Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta -amyloid peptide em in vitro em and in patients. Frontiers in Bioscience - Landmark, 2002, 7, a50-59.	3.0	41
118	Implications of Amyloid Precursor Protein and Subsequent β-Amyloid Production to the Pharmacotherapy of Alzheimer's Disease. Pharmacotherapy, 2002, 22, 1547-1563.	2.6	9
119	24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. Journal of Psychiatric Research, 2002, 36, 27-32.	3.1	218
121	Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Research, 2002, 958, 100-111.	2.2	40
122	Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis1 1This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease.―The full list of papers may be found on the homepage of the journal Free Radical Biology and Medicine. 2002. 33. 173-181.	2.9	70
123	Association between highâ€density lipoprotein and cognitive impairment in the oldest old. Annals of Neurology, 2002, 51, 716-721.	5.3	164
124	Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26â€week randomized, placeboâ€controlled, doubleâ€blind trial. Annals of Neurology, 2002, 52, 346-350.	5.3	372
125	Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. Journal of Neuroscience Research, 2002, 68, 627-635.	2.9	32
126	Amyloid βâ€protein affects cholesterol metabolism in cultured neurons: Implications for pivotal role of cholesterol in the amyloid cascade. Journal of Neuroscience Research, 2002, 70, 438-446.	2.9	53
127	Cholesterol and pathological processes in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 361-366.	2.9	69
128	Neuroplasticity in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 402-437.	2.9	102
129	Vascular risk factors, ApoE ?4 allele, and gender and the risk of Alzheimer's disease: perspectives on prevention. Drug Development Research, 2002, 56, 85-94.	2.9	9
130	Therapeutic strategies of Alzheimer's disease through manipulation of A? metabolism: a focus on A?-degrading peptidase, neprilysin. Drug Development Research, 2002, 56, 171-183.	2.9	6
131	Targeting APP metabolism for the treatment of Alzheimer's disease. Drug Development Research, 2002, 56, 211-227.	2.9	15
132	Current drug targets for Alzheimer's disease treatment. Drug Development Research, 2002, 56, 267-281.	2.9	181

#	Article	lF	CITATIONS
133	Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. Drug Development Research, 2002, 56, 415-420.	2.9	4
134	Statin therapy for Alzheimer's disease. Journal of Molecular Neuroscience, 2002, 19, 155-161.	2.3	152
135	Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?. Journal of Molecular Neuroscience, 2002, 19, 209-212.	2.3	3
136	Prevention of Alzheimer's disease: Where we stand. Current Neurology and Neuroscience Reports, 2002, 2, 392-399.	4.2	9
138	Statins: the new aspirin?. Cellular and Molecular Life Sciences, 2002, 59, 1771-1786.	5.4	86
139	Potential neurotoxic inflammatory responses to $A^{\hat{l}2}$ vaccination in humans. Journal of Neural Transmission, 2002, 109, 1081-1087.	2.8	41
140	Kosten-Effektivitïż½t der KHK-Prïż½vention. Clinical Research in Cardiology, 2002, 91, 1-1.	1.1	5
141	Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Research in Cardiology, 2002, 97, 105-116.	5.9	187
142	Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. European Archives of Psychiatry and Clinical Neuroscience, 2002, 252, 63-67.	3.2	101
143	Use of Lipid‣owering Drugs in Older Adults With and Without Dementia: A Communityâ€Based Epidemiological Study. Journal of the American Geriatrics Society, 2002, 50, 1852-1856.	2.6	93
144	Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Molecular Psychiatry, 2002, 7, 899-902.	7.9	139
145	Alzheimer's disease: treatments in discovery and development. Nature Neuroscience, 2002, 5, 1055-1057.	14.8	154
146	Therapeutic strategies for Alzheimer's disease. Nature Reviews Drug Discovery, 2002, 1, 859-866.	46.4	167
147	Prospects for the prevention of dementia. Australasian Journal on Ageing, 2002, 21, 9-13.	0.9	12
148	Vascular Basis of Alzheimer's Pathogenesis. Annals of the New York Academy of Sciences, 2002, 977, 196-215.	3.8	217
149	Cholesterol and Cognition. Annals of the New York Academy of Sciences, 2002, 977, 356-366.	3.8	26
150	Cholesterol in Alzheimer's Disease and Tauopathy. Annals of the New York Academy of Sciences, 2002, 977, 367-375.	3.8	116
152	Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cellular and Molecular Neurobiology, 2002, 22, 545-563.	3.3	65

#	Article	IF	CITATIONS
153	The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and Appl processing. EMBO Journal, 2002, 21, 6367-6376.	7.8	113
154	Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease. NeuroMolecular Medicine, 2002, 1, 1-32.	3.4	181
155	Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol. Journal of Molecular Neuroscience, 2003, 20, 395-406.	2.3	47
156	The Role of Cholesterol in Pathogenesis of Alzheimer's Disease: Dual Metabolic Interaction between Amyloid β-Protein and Cholesterol. Molecular Neurobiology, 2003, 27, 1-12.	4.0	81
157	E <scp>PIDEMIOLOGY OF</scp> N <scp>EURODEGENERATION</scp> . Annual Review of Neuroscience, 2003, 26, 81-104.	10.7	451
158	Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease. Neurochemical Research, 2003, 28, 979-986.	3.3	21
159	Plasticity and the spread of Alzheimer's disease-like changes. Neurochemical Research, 2003, 28, 1715-1723.	3.3	9
160	Beta-amyloid and cholinergic neurons. Neurochemical Research, 2003, 28, 499-506.	3.3	26
162	Brain region-dependent increases in ?-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. Journal of Neural Transmission, 2003, 110, 641-649.	2.8	37
164	Treatment of Alzheimer's disease; current status and new perspectives. Lancet Neurology, The, 2003, 2, 539-547.	10.2	664
165	Position of the American Dietetic Association and Dietitians of Canada: Vegetarian diets. Journal of the American Dietetic Association, 2003, 103, 748-765.	1.1	267
166	Cognitive Impairment Associated with Atorvastatin and Simvastatin. Pharmacotherapy, 2003, 23, 1663-1667.	2.6	123
167	The Role of Lipid-Lowering Drugs in Cognitive Function: A Meta-Analysis of Observational Studies. Pharmacotherapy, 2003, 23, 726-730.	2.6	61
168	Statin-Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature. Pharmacotherapy, 2003, 23, 871-880.	2.6	308
169	Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Developmental Brain Research, 2003, 146, 87-98.	1.7	148
171	Statin effects on cholesterol micro-domains in brain plasma membranes. Biochemical Pharmacology, 2003, 65, 843-856.	4.4	162
172	Expression of acetoacetyl-CoA synthetase, a novel cytosolic ketone body-utilizing enzyme, in human brain. Biochemical Pharmacology, 2003, 65, 989-994.	4.4	25
173	Prevention of stroke and dementia with statins. American Journal of Cardiology, 2003, 91, 23-29.	1.6	119

#	Article	IF	CITATIONS
174	Treating the full spectrum of dementia with memantine. International Journal of Geriatric Psychiatry, 2003, 18, S41-S46.	2.7	32
175	Cholesterol paradox: Is high total or low HDL cholesterol level a risk for Alzheimer's disease?. Journal of Neuroscience Research, 2003, 72, 141-146.	2.9	110
176	ADAMs family members as amyloid precursor protein αâ€secretases. Journal of Neuroscience Research, 2003, 74, 342-352.	2.9	402
177	Association of the C766T polymorphism of the lowâ€density lipoprotein receptorâ€related protein gene with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2003, 121B, 128-130.	1.7	38
179	Treatment of mild cognitive impairment: rationale, present and future strategies. Acta Neurologica Scandinavica, 2003, 107, 83-93.	2.1	19
180	Arterial hypertension and ischaemic stroke. Acta Neurologica Scandinavica, 2003, 107, 241-251.	2.1	41
181	Cholesterol is necessary both for the toxic effect of Aβ peptides on vascular smooth muscle cells and for Aβ binding to vascular smooth muscle cell membranes. Journal of Neurochemistry, 2003, 84, 471-479.	3.9	90
182	An Outbreak of Severe Acute Respiratory Syndrome in a Nursing Home. Journal of the American Geriatrics Society, 2003, 51, 1504-1505.	2.6	9
183	Benefits of Statins in the Elderly. Journal of the American Geriatrics Society, 2003, 51, 1509-1510.	2.6	0
184	Pathology and Pathways of Alzheimer's Disease with an Update on New Developments in Treatment. Journal of the American Geriatrics Society, 2003, 51, S314-S320.	2.6	39
186	Blockade of HMG oA reductase activity causes changes in microtubuleâ€stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. European Journal of Neuroscience, 2003, 17, 93-102.	2.6	87
188	Long-term statin use and psychological well-being. Journal of the American College of Cardiology, 2003, 42, 690-697.	2.8	121
189	The Pleiotropic Effects of HMG-CoA Reductase Inhibitors. Drugs, 2003, 63, 139-152.	10.9	47
190	Î <sup>3</sup> -Secretase Activity Is Present in Rafts but Is Not Cholesterol-Dependent. Biochemistry, 2003, 42, 13977-13986.	2.5	74
191	Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. Journal of Cell Biology, 2003, 160, 113-123.	5.2	992
192	Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Progress in Neurobiology, 2003, 71, 83-248.	5.7	176
193	Association of Aortic Atherosclerosis with Cerebral β-Amyloidosis and Learning Deficits in a Mouse Model of Alzheimer's Disease. American Journal of Pathology, 2003, 163, 2155-2164.	3.8	125
194	Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics. Annual Review of Pharmacology and Toxicology, 2003, 43, 545-584.	9.4	785

#	Article	IF	CITATIONS
195	NSAIDs and enantiomers of flurbiprofen target Î <sup>3</sup> -secretase and lower AÎ <sup>2</sup> 42 in vivo. Journal of Clinical Investigation, 2003, 112, 440-449.	8.2	476
196	Alzheimer's disease and angiogenesis. Lancet, The, 2003, 361, 605-608.	13.7	263
197	Alzheimer's disease and angiogenesis. Lancet, The, 2003, 361, 1299.	13.7	62
198	Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1610, 281-290.	2.6	145
199	β-Amyloid-specific upregulation of stearoyl coenzyme A desaturase-1 in macrophages. Biochemical and Biophysical Research Communications, 2003, 303, 302-305.	2.1	23
200	Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. Steroids, 2003, 68, 685-691.	1.8	14
201	Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans. Neuroscience Letters, 2003, 350, 161-164.	2.1	46
202	Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiology of Aging, 2003, 24, 147-155.	3.1	76
203	ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiology of Aging, 2003, 24, 421-426.	3.1	148
204	Aβ42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3β signaling-dependent mechanism. Neurobiology of Aging, 2003, 24, 437-451.	3.1	71
205	Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice. Neurobiology of Aging, 2003, 24, 637-643.	3.1	131
206	High cholesterol affects platelet APP processing in controls and in AD patients. Neurobiology of Aging, 2003, 24, 631-636.	3.1	24
207	Biological markers for therapeutic trials in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 521-536.	3.1	249
208	Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 893-902.	3.1	85
209	Co-localization of cholesterol, apolipoprotein E and fibrillar Aβ in amyloid plaques. Molecular Brain Research, 2003, 110, 119-125.	2.3	108
210	Identification of neuronal plasma membrane microdomains that colocalize β-amyloid and presenilin: implications for β-amyloid precursor protein processing. Neuroscience, 2003, 120, 291-300.	2.3	25
211	The cholesterol-lowering drug Probucol increases apolipoprotein e production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience, 2003, 121, 99-110.	2.3	64
212	Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends in Molecular Medicine, 2003, 9, 94-101.	6.7	149

ARTICLE IF CITATIONS # Evolution by Phenotype: A Biomedical Perspective. Perspectives in Biology and Medicine, 2003, 46, 213 0.5 32 159-182. Cyp46 (24S-Cholesterol Hydroxylase). Archives of Neurology, 2003, 60, 16. 214 4.5 Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery 215 2.7 6 Disease. Drugs and Aging, 2003, 20, 585-595. Dietary Lipids in the Aetiology of Alzheimer???s Disease. Drugs and Aging, 2003, 20, 399-418. HMG-CoA Reductase Inhibitors in Osteoporosis. Drugs and Aging, 2003, 20, 321-336. 217 2.7 11 Statin Therapy in the Elderly. Drugs and Aging, 2003, 20, 263-275. 2.7 Non-cholinergic strategies have a potential role in the management of Alzheimer's disease. Drugs and 219 0.6 0 Therapy Perspectives, 2003, 19, 7-10. Preventing and treating Alzheimer's disease: strategies and prospects. Expert Review of 2.8 Neurotherapeutics, 2003, 3, 565-569. Reduction in Levels of 24S-Hydroxycholesterol by Statin Treatment in Patients With Alzheimer Disease. 221 4.5 155 Archives of Neurology, 2003, 60, 510. Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels. Archives of Neurology, 4.5 2003, 60, 958. Serum lipids and memory in a population based cohort of middle age women. Journal of Neurology, 223 1.9 73 Neurosurgery and Psychiatry, 2003, 74, 1530-1535. Cholesterol. Journal of Lipid Research, 2003, 44, 1423-1430. 224 4.2 Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid Î<sup>2</sup> Peptide Secretion. Journal of 225 3.4 160 Biological Chemistry, 2003, 278, 27688-27694. Dietary fat modulation of apoA-II metabolism and prevention of senile amyloidosis in the senescence-accelerated mouse. Journal of Lipid Research, 2003, 44, 762-769. 4.2 Early Embryonic Lethality Caused by Targeted Disruption of the 3-Hydroxy-3-methylglutaryl-CoA 227 3.4 94 Reductase Gene. Journal of Biological Chemistry, 2003, 278, 42936-42941. Copper, Â-amyloid, and Alzheimer's disease: Tapping a sensitive connection. Proceedings of the National 134 Academy of Sciences of the United States of America, 2003, 100, 11193-11194. Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and 229 332 3.4 ADAM17 (TACE). Journal of Biological Chemistry, 2003, 278, 38829-38839. Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease. Journal of Lipid Research, 2003, 4.2 69 44, 2019-2029.

#	Article	IF	CITATIONS
231	Treatment with Simvastatin in Patients with Alzheimer's Disease Lowers Both α- and β-Cleaved Amyloid Precursor Protein. Dementia and Geriatric Cognitive Disorders, 2003, 16, 25-30.	1.5	102
232	Rapid Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 156-157.	2.4	27
233	Dietary Fats and the Risk of Incident Alzheimer Disease. Archives of Neurology, 2003, 60, 194.	4.5	436
234	Managing Alzheimer Dementia Tomorrow. Journal of the American Board of Family Medicine, 2003, 16, 423-434.	1.5	3
235	Anti-Amyloidogenic Effect of Allium sativum in Alzheimer's Transgenic Model Tg2576. Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals, 2003, 3, 95-107.	0.1	32
236	Progenitor endothelial cell involvement in Alzheimer's disease. Neurological Research, 2003, 25, 617-624.	1.3	6
237	Association of Abnormal Serum Lipids in Elderly Persons With Atherosclerotic Vascular Disease and Dementia, Atherosclerotic Vascular Disease Without Dementia, Dementia Without Atherosclerotic Vascular Disease, and No Dementia or Atherosclerotic Vascular Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M859-M861.	3.6	23
238	Cholesterol Distribution in the Golgi Complex of DITNC1 Astrocytes Is Differentially Altered by Fresh and Aged Amyloid à¤Peptide-(1–42). Journal of Biological Chemistry, 2003, 278, 17150-17157.	3.4	26
239	Cholesterol, β-amyloid, and Alzheimer's disease. Advances in Cell Aging and Gerontology, 2003, 12, 163-175.	0.1	0
240	22R-Hydroxycholesterol and 9-cis-Retinoic Acid Induce ATP-binding Cassette Transporter A1 Expression and Cholesterol Efflux in Brain Cells and Decrease Amyloid Î <sup>2</sup> Secretion. Journal of Biological Chemistry, 2003, 278, 13244-13256.	3.4	215
241	Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11735-11740.	7.1	346
243	Autosomal Recessive Hypercholesterolemia Protein Interacts with and Regulates the Cell Surface Level of Alzheimer's Amyloid β Precursor Protein. Journal of Biological Chemistry, 2003, 278, 31843-31847.	3.4	27
244	Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology, 2003, 60, 2006-2007.	1.1	31
245	Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease. Archives of Internal Medicine, 2003, 163, 1053.	3.8	250
246	Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurological Research, 2003, 25, 675-680.	1.3	98
247	A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease. Current Drug Targets, 2003, 4, 97-112.	2.1	198
248	Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurological Research, 2003, 25, 567-580.	1.3	69
249	The risk of dementia in relation to statins and other lipid lowering agents. Neurological Research, 2003, 25, 601-604.	1.3	24

		PORT	
# 250	ARTICLE Brain Cholesterol, Statins and Alzheimer's Disease. Pharmacopsychiatry, 2003, 36, 113-119.	IF 3.3	Citations
251	Cholesterol Modulates Amyloid Beta-peptide's Membrane Interactions. Pharmacopsychiatry, 2003, 36, 136-143.	3.3	42
252	Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology, 2003, 61, 199-205.	1.1	291
254	24S-Hydroxycholesterol: a Marker of Brain Cholesterol Metabolism. Pharmacopsychiatry, 2003, 36, 102-106.	3.3	61
255	Cholesterol and Tau Protein - Findings in Alzheimer's and Niemann Pick C's Disease. Pharmacopsychiatry, 2003, 36, 120-126.	3.3	41
256	Cholesterol, Synaptic Function and Alzheimer's Disease. Pharmacopsychiatry, 2003, 36, 107-112.	3.3	28
257	Position of the American Dietetic Association and Dietitians of Canada: Vegetarian Diets. Canadian Journal of Dietetic Practice and Research, 2003, 64, 62-81.	0.6	60
258	Pharmacotherapy for Alzheimer's Disease: 2002. Clinical Neuropharmacology, 2003, 26, 93-101.	0.7	16
259	Is Cholesterol a Culprit in Alzheimer's Disease?. International Psychogeriatrics, 2003, 15, 153-159.	1.0	15
260	Dementia Update 2003. Alzheimer Disease and Associated Disorders, 2003, 17, 245-258.	1.3	32
261	The Role of Cardiovascular Risk Factors in Alzheimer's Disease. CNS Spectrums, 2003, 8, 824-831.	1.2	18
262	Current Concepts in the Prevention of Alzheimer's Disease. CNS Spectrums, 2003, 8, 846-853.	1.2	16
263	The incorporation and metabolism of amyloid-β into chylomicron-like lipid emulsions. Journal of Alzheimer's Disease, 2003, 5, 179-188.	2.6	29
264	Statins and Stroke. Therapie, 2003, 58, 49-58.	1.0	3
266	Cerebrovascular Disease in Italy and Europe: It Is Necessary to Prevent a â€~Pandemia'. Gerontology, 2003, 49, 69-79.	2.8	8
267	Prevention of Alzheimer's Disease and Other Dementias. Journal of Pharmacy Practice and Research, 2003, 33, 138-143.	0.8	2
268	Increased Brain Î <sup>2</sup> -Amyloid Load, Phosphorylated Tau, and Risk of Alzheimer Disease Associated With an Intronic CYP46 Polymorphism. Archives of Neurology, 2003, 60, 29.	4.5	210
269	Statins and their role in vascular protection. Clinical Science, 2003, 105, 251-266.	4.3	100

		Report	
#	Article	IF	CITATIONS
270	Emerging Therapeutics for Alzheimer's Disease: An Avenue of Hope. CNS Spectrums, 2003, 8, 834-845.	1.2	8
271	2 Epidemiologie psychischer StĶrungen im Alter. , 2003, , .		0
272	23 Antidementive Therapie. , 2003, , .		0
274	Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances β-Amyloid Production <i>In Vivo</i> . Journal of Neuroscience, 2003, 23, 5645-5649.	3.6	170
275	Pharmacological Treatment of Dementia: A Review. , 2003, , 199-278.		1
276	NATURAL PRODUCTS AS PHARMACEUTICALS AND SOURCES FOR LEAD STRUCTURES. , 2003, , 91-109.		7
277	Molecular Mechanisms of Neurodegenerative Disorders. , 0, , 377-409.		1
278	3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity. Journal of Neuroscience, 2003, 23, 11104-11111.	3.6	236
279	Dietary Fats and the Risk of Incident Alzheimer Disease—Correction. Archives of Neurology, 2003, 60, 1072.	4.5	3
280	Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia. Journal of Atherosclerosis and Thrombosis, 2004, 11, 253-264.	2.0	92
281	Strategies for the prevention and treatment of statin-induced myopathy: Is there a role for ubiquinone supplementation?. American Journal of Health-System Pharmacy, 2004, 61, 515-519.	1.0	22
282	Statins in the Primary Prevention of Atherosclerosis-Related Events. , 2004, , 53-92.		1
283	Effects of Statins on Lymphocyte Function–Associated Antigen-1. , 2004, , 285-295.		0
284	Could Lipoprotein Lipase Play a Role in Alzheimer's Disease?. Scientific World Journal, The, 2004, 4, 531-535.	2.1	7
286	Linking lipids, Alzheimer's and LXRs?. Nuclear Receptor Signaling, 2004, 2, nrs.02001.	1.0	9
288	Hormone therapy and Alzheimer's disease: benefit or harm?. Expert Opinion on Pharmacotherapy, 2004, 5, 389-406.	1.8	38
289	Association between Statin Use and Alzheimer's Disease. Neuroepidemiology, 2004, 23, 94-98.	2.3	183
291	The Effects of Gender and CYP46 and Apo E Polymorphism on 24S-Hydroxycholesterol Levels in Alzheimers Patients Treated with Statins. Current Alzheimer Research, 2004, 1, 71-77.	1.4	20

#	Article	IF	CITATIONS
292	Secretases as therapeutic targets in Alzheimer's disease: patents 2000 – 2004. Expert Opinion on Therapeutic Patents, 2004, 14, 1403-1420.	5.0	16
293	Brain Cholesterol: Long Secret Life Behind a Barrier. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 806-815.	2.4	866
294	Young onset dementia. Postgraduate Medical Journal, 2004, 80, 125-139.	1.8	139
295	Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. Journal of Lipid Research, 2004, 45, 1375-1397.	4.2	865
296	A lipid boundary separates APP and secretases and limits amyloid β-peptide generation. Journal of Cell Biology, 2004, 167, 809-812.	5.2	75
297	Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease. Journal of Biological Chemistry, 2004, 279, 34674-34681.	3.4	238
298	Causes and Consequences of Disturbances of Cerebral Glucose Metabolism in Sporadic Alzheimer Disease: Therapeutic Implications. Advances in Experimental Medicine and Biology, 2004, 541, 135-152.	1.6	156
299	Statin Therapy: Having the Good Without the Bad. Hypertension, 2004, 43, 1171-1172.	2.7	9
300	Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. Journal of Lipid Research, 2004, 45, 186-193.	4.2	277
301	Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of the amyloidâ€Ĵ² peptide. FASEB Journal, 2004, 18, 836-838.	0.5	82
302	Mixed Dementia. JAMA - Journal of the American Medical Association, 2004, 292, 2901.	7.4	293
303	The Role of Cholesterol and Statins in Alzheimer's Disease. Annals of Pharmacotherapy, 2004, 38, 91-98.	1.9	61
304	Enzyme blockade: a nonradioactive method to determine the absolute rate of cholesterol synthesis in the brain. Journal of Lipid Research, 2004, 45, 1952-1957.	4.2	8
305	SREBP-1a Polymorphism Influences the Risk of Alzheimer's Disease in Carriers of the ApoE4 Allele. Dementia and Geriatric Cognitive Disorders, 2004, 18, 245-249.	1.5	23
306	Mouse Models of Alzheimer's Disease: Insight into Treatment. Reviews in the Neurosciences, 2004, 15, 353-370.	2.9	101
307	Apomine, a Novel Hypocholesterolemic Agent, Accelerates Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase and Stimulates Low Density Lipoprotein Receptor Activity. Journal of Biological Chemistry, 2004, 279, 6465-6473.	3.4	29
308	Inhibition of Geranylgeranylation Mediates the Effects of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors on Microglia. Journal of Biological Chemistry, 2004, 279, 48238-48245.	3.4	63
309	Patients with Alzheimer's Disease May Be Particularly Susceptible to Adverse Effects of Statins. Dementia and Geriatric Cognitive Disorders, 2004, 17, 109-116.	1.5	24

#	Article	IF	Citations
310	Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology, 2004, 62, 275-280.	1.1	443
311	BACE1 and Presenilin: Two Unusual Aspartyl Proteases Involved in Alzheimer's Disease. Neurodegenerative Diseases, 2004, 1, 168-174.	1.4	25
312	Plasmin Deficiency in Alzheimer's Disease Brains: Causal or Casual?. Neurodegenerative Diseases, 2004, 1, 205-212.	1.4	22
313	Problems and Solutions in the Genetic Analysis of Late-Onset Alzheimer's Disease. Neurodegenerative Diseases, 2004, 1, 213-217.	1.4	11
314	Treatment and Prevention of Ageâ€Related Macular Degeneration. Journal of Pharmacy Practice and Research, 2004, 34, 53-57.	0.8	1
315	Transgenic mouse models of Alzheimer's disease: How useful have they been for therapeutic development?. Briefings in Functional Genomics & Proteomics, 2004, 3, 47-59.	3.8	90
316	Pleiotropic Effects of Statins. Annual Reports in Medicinal Chemistry, 2004, 39, 239-258.	0.9	2
317	Neuronal membrane cholesterol loss enhances amyloid peptide generation. Journal of Cell Biology, 2004, 167, 953-960.	5.2	308
318	Hypercholesterolemia, HMG-CoA Reductase Inhibitors, and Risk of Intracerebral Hemorrhage. Stroke, 2004, 35, 1360-1364.	2.0	73
319	Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics, 2004, 5, 1049-1105.	1.3	29
320	Statin therapy and risk of dementia in the elderly. Neurology, 2004, 63, 1624-1628.	1.1	243
321	Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia. Archives of Neurology, 2004, 61, 705.	4.5	346
322	Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology, 2004, 62, 1573-1579.	1.1	270
323	The care gap: underuse of statin therapy in the elderly. International Journal of Clinical Practice, 2004, 58, 777-785.	1.7	22
324	Do statins slow down Alzheimer's disease? A review. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 209-213.	1.5	49
325	Proton magnetic resonance spectroscopy and single photon emission computed tomography study of the brain in asymptomatic young hyperlipidaemic Asian Indians in North India show early abnormalities. Clinical Endocrinology, 2004, 61, 182-189.	2.4	14
326	Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. Journal of Neurochemistry, 2004, 89, 939-950.	3.9	201
327	Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. Journal of Neurochemistry, 2004, 90, 1005-1010.	3.9	69

		CITATION REPORT		
#	Article		IF	CITATIONS
328	Epidemiology and prevalence of Alzheimer's disease and risk factors. Psychogeriatrics,	2004, 4, 120-123.	1.2	1
329	Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clinical Genet 1-16.	ics, 2004, 66,	2.0	56
330	Strategies for disease modification in Alzheimer's disease. Nature Reviews Neuroscienc 677-685.	:e, 2004, 5,	10.2	409
331	Pathways towards and away from Alzheimer's disease. Nature, 2004, 430, 631-639.		27.8	2,687
332	Increased iron staining in the cerebral cortex of cholesterol fed rabbits. Mechanisms of Development, 2004, 125, 305-313.	Ageing and	4.6	18
333	Pharmacoepidemiology I: A Review of Pharmacoepidemiologic Study Designs. Pharmac 24, 964-969.	otherapy, 2004,	2.6	46
334	Central retinal vein occlusion associated with liquorice ingestion. Clinical and Experime Ophthalmology, 2004, 32, 341-341.	ntal	2.6	6
335	AMD: to supplement or not?. Clinical and Experimental Ophthalmology, 2004, 32, 341	-343.	2.6	11
337	Alzheimer's Disease Therapeutics: New Approaches to an Ageing Problem. IUBMB Life,	2004, 56, 203-208.	3.4	5
338	Proteases and Lipoprotein Receptors in Alzheimer's Disease. Cell Biochemistry and Bio 139-178.	physics, 2004, 41,	1.8	6
339	<i>APOE</i> Genotype Effects on Alzheimer's Disease Onset and Epidemiolo Molecular Neuroscience, 2004, 23, 157-166.	ogy. Journal of	2.3	199
340	ApoE-Dependent Plasticity in Alzheimer's Disease. Journal of Molecular Neuroscience, 2	2004, 23, 167-180.	2.3	47
341	Cholesterol Efflux as a Critical Component of Alzheimer's Disease Pathogenesis. Journa Molecular Neuroscience, 2004, 23, 219-224.	ll of	2.3	41
342	Loss of Apolipoprotein E Receptor LR11 in Alzheimer Disease. Archives of Neurology, 2	004, 61, 1200-5.	4.5	286
343	Links Between the Pathology of Alzheimer's Disease and Vascular Dementia. Neuroche 2004, 29, 1257-1266.	mical Research,	3.3	89
344	Effects of Lovastatin and Pravastatin on Amyloid Processing and Inflammatory Responses Brain. Neurochemical Research, 2004, 29, 1897-1911.	se in TgCRND8	3.3	70
345	Lipid-Lowering Effects of Ethyl 2-Phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in Rodents. 2004, 9, 134-157.	Molecules,	3.8	25
346	Iron, Atherosclerosis, and Neurodegeneration: A Key Role for Cholesterol in Promoting Iron-Dependent Oxidative Damage?. Annals of the New York Academy of Sciences, 200	94, 1012, 51-64.	3.8	74

#	Article	IF	CITATIONS
347	Variants of CYP46A1 may interact with age and APOE to influence CSF A�42 levels in Alzheimer?s disease. Human Genetics, 2004, 114, 581-587.	3.8	60
348	Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases. Current Atherosclerosis Reports, 2004, 6, 36-41.	4.8	10
349	Amyloidβ-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. Journal of Peptide Science, 2004, 10, 229-248.	1.4	251
350	HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. Journal of Neurochemistry, 2004, 89, 24-32.	3.9	93
351	Life long changes in cognitive ability are associated with prescribed medications in old age. International Journal of Geriatric Psychiatry, 2004, 19, 327-332.	2.7	53
352	Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to ?-amyloid metabolism. Human Mutation, 2004, 23, 358-367.	2.5	120
353	Lovastatin modulation of microglial activation via suppression of functional CD40 expression. Journal of Neuroscience Research, 2004, 78, 167-176.	2.9	46
354	Differential effects of lipid-lowering agents on human cholinesterases. Clinical Biochemistry, 2004, 37, 42-49.	1.9	32
355	Combination Therapy in Alzheimer???s Disease. CNS Drugs, 2004, 18, 827-844.	5.9	152
356	Cholesterol homeostasis and the pathophysiology of Alzheimer's disease. Expert Review of Neurotherapeutics, 2004, 4, 823-829.	2.8	20
357	Toward Alzheimer Therapies Based on Genetic Knowledge. Annual Review of Medicine, 2004, 55, 15-25.	12.2	39
359	The Risk of Cancer in Users of Statins. Journal of Clinical Oncology, 2004, 22, 2388-2394.	1.6	475
360	Biomarkers of Alzheimer disease in plasma. NeuroRx, 2004, 1, 226-234.	6.0	241
361	Treatment Strategies in Alzheimer???s Disease with a Focus on Early Pharmacological Interventions. Drugs and Aging, 2004, 21, 415-426.	2.7	15
362	On the horizon: pathways for drug development in Alzheimer's disease. Clinics in Geriatric Medicine, 2004, 20, 141-152.	2.6	3
363	Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treatment Reviews, 2004, 30, 609-641.	7.7	270
364	Cholesterol modulates ligand binding and G-protein coupling to serotonin1A receptors from bovine hippocampus. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1663, 188-200.	2.6	220
365	High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids, 2004, 69, 431-438.	1.8	108

#	Article	IF	CITATIONS
366	Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: Part II. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 472-477.	1.6	27
367	ApoAl Deficiency Results in Marked Reductions in Plasma Cholesterol But No Alterations in Amyloid-β Pathology in a Mouse Model of Alzheimer's Disease-Like Cerebral Amyloidosis. American Journal of Pathology, 2004, 165, 1413-1422.	3.8	52
368	A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain. Neurobiology of Disease, 2004, 15, 510-519.	4.4	33
369	APP intracellular domain is increased and soluble Aβ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiology of Disease, 2004, 16, 124-132.	4.4	80
370	Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population. Neuroscience Letters, 2004, 363, 139-143.	2.1	40
371	Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. Neuroscience Letters, 2004, 369, 87-92.	2.1	45
372	Plasma β-amyloid (Aβ) 40 concentration, lipid status and age in humans. Neuroscience Letters, 2004, 367, 48-50.	2.1	17
373	Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. Neuroscience Letters, 2004, 367, 228-231.	2.1	36
374	APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease. Neuroscience Letters, 2004, 368, 148-150.	2.1	63
375	Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese. Neuroscience Letters, 2004, 369, 104-107.	2.1	38
376	Rosuvastatin reduces caspase-3 activity and up-regulates α-secretase in human neuroblastoma SH-SY5Y cells exposed to Aβ. Neuroscience Letters, 2004, 371, 209-214.	2.1	29
377	Increased caveolin-1 expression in Alzheimer's disease brain. Neurobiology of Aging, 2004, 25, 753-759.	3.1	110
378	Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiology of Aging, 2004, 25, 977-989.	3.1	90
379	High carbohydrate diets and Alzheimer's disease. Medical Hypotheses, 2004, 62, 689-700.	1.5	64
380	Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. American Journal of Ophthalmology, 2004, 137, 615-624.	3.3	84
381	Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2070-2075.	7.1	967
382	Targets for Alzheimer's disease: lessons learnt from flies. Drug Discovery Today: TARGETS, 2004, 3, 64-70.	0.5	2
383	Cholesterol and the Biology of Alzheimer's Disease. Neuron, 2004, 41, 7-10.	8.1	263

			-
#	Article	IF	CITATIONS
384	Pharmacotherapeutic approaches to the prevention of Alzheimer's disease. American Journal of Geriatric Pharmacotherapy, 2004, 2, 119-132.	3.0	39
385	Evidence-based pharmacotherapy of Alzheimer's disease. International Journal of Neuropsychopharmacology, 2004, 7, 351-369.	2.1	70
386	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet, The, 2004, 363, 1139-1146.	13.7	510
387	Association of dyslipidemia and effects of statins on nonmacrovascular diseases. Clinical Therapeutics, 2004, 26, 337-351.	2.5	21
388	Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clinical Therapeutics, 2004, 26, 615-630.	2.5	106
389	Methods of Regulating Alzheimer Pathogenesis: Diet, Oxidative Damage and Inflammation. , 2004, , 1-16.		0
390	Plasma Levels of β-Amyloid(1-40), β-Amyloid(1-42), and Total β-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins. Archives of Neurology, 2004, 61, 333.	4.5	109
391	Drugs and Human Memory (Part 2). Anesthesiology, 2004, 100, 1277-1297.	2.5	50
392	APOE promoter, ACE1 and CYP46 polymorphisms and β-amyloid in Alzheimer's disease. NeuroReport, 2004, 15, 95-98.	1.2	37
393	Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration*1. American Journal of Ophthalmology, 2004, 137, 615-624.	3.3	127
394	Cholesterol, statins and dementia. Current Opinion in Lipidology, 2004, 15, 667-672.	2.7	76
395	Conceptual Foundations of the UCSD Statin Study. Archives of Internal Medicine, 2004, 164, 153.	3.8	47
396	Hypolipidemic Drugs Can Change the Composition of Rat Brain Lipids. Tohoku Journal of Experimental Medicine, 2004, 204, 299-308.	1.2	15
397	Pathogenesis of Alzheimer Disease: Metabolic Factors. , 2004, , 303-353.		0
398	Iron, neuroinflammation, and Alzheimer's disease. Journal of Alzheimer's Disease, 2005, 8, 183-200.	2.6	112
399	Advances On Biological Markers In Early Diagnosis Of Alzheimer Disease. Advances in Clinical Chemistry, 2005, 39, 107-129.	3.7	2
400	Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. Journal of Alzheimer's Disease, 2005, 7, 303-314.	2.6	25
401	Neuroprotection and Neurodegenerative Diseases. Alzheimer Disease and Associated Disorders, 2005, 19, 226-239.	1.3	27

#	Article	IF	CITATIONS
402	Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression?. Current Opinion in Lipidology, 2005, 16, 619-623.	2.7	23
403	Dementia Update 2005. Alzheimer Disease and Associated Disorders, 2005, 19, 100-117.	1.3	58
404	Clinical implications for statin pleiotropy. Current Opinion in Lipidology, 2005, 16, 624-629.	2.7	123
405	Statins and Cognition: What Can We Learn from Existing Randomized Trials?. CNS Spectrums, 2005, 10, 867-875.	1.2	22
406	The Future of Statins: Alzheimer's Disease?. The Consultant Pharmacist, 2005, 20, 663-673.	0.4	2
407	Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I. Current Opinion in Urology, 2005, 15, 1-6.	1.8	12
409	Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochemical Society Transactions, 2005, 33, 335-338.	3.4	107
410	Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033-1036.	3.4	35
411	Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091-1093.	3.4	6
419			
412	Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091.	3.4	10
412	Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091. Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033.	3.4 3.4	10 63
412 413 414	<ul> <li>Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091.</li> <li>Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033.</li> <li>Novel and simple high-performance liquid chromatographic method for determination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 307-313.</li> </ul>	3.4 3.4 2.3	10 63 7
412 413 414 415	Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091. Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033. Novel and simple high-performance liquid chromatographic method for determination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 307-313. Is Hypercholesterolemia a Risk Factor for Alzheimer's Disease?. Molecular Neurobiology, 2005, 31, 185-192.	<ul><li>3.4</li><li>3.4</li><li>2.3</li><li>4.0</li></ul>	10 63 7 32
<ul> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> </ul>	<ul> <li>Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091.</li> <li>Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033.</li> <li>Novel and simple high-performance liquid chromatographic method for determination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 307-313.</li> <li>Is Hypercholesterolemia a Risk Factor for Alzheimer's Disease?. Molecular Neurobiology, 2005, 31, 185-192.</li> <li>Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. Journal of Neurochemistry, 2005, 92, 1386-1398.</li> </ul>	<ul> <li>3.4</li> <li>3.4</li> <li>2.3</li> <li>4.0</li> <li>3.9</li> </ul>	10 63 7 32 185
<ul> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> <li>417</li> </ul>	Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091.         Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033.         Novel and simple high-performance liquid chromatographic method for determination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 307-313.         Is Hypercholesterolemia a Risk Factor for Alzheimer's Disease?. Molecular Neurobiology, 2005, 31, 185-192.         Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. Journal of Neurochemistry, 2005, 92, 1386-1398.         Contributors to white matter damage in the frontal lobe in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2005, 31, 623-631.	<ul> <li>3.4</li> <li>3.4</li> <li>2.3</li> <li>4.0</li> <li>3.9</li> <li>3.2</li> </ul>	10 63 7 32 185 49
<ul> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> <li>417</li> <li>418</li> </ul>	Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091.         Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033.         Novel and simple high-performance liquid chromatographic method for determination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 307-313.         Is Hypercholesterolemia a Risk Factor for Alzheimer's Disease?. Molecular Neurobiology, 2005, 31, 185-192.         Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. Journal of Neurochemistry, 2005, 92, 1386-1398.         Contributors to white matter damage in the frontal lobe in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2005, 31, 623-631.         Statins âC" a cure-all for the brain?. Nature Reviews Neuroscience, 2005, 6, 325-331.	<ul> <li>3.4</li> <li>3.4</li> <li>2.3</li> <li>4.0</li> <li>3.9</li> <li>3.2</li> <li>10.2</li> </ul>	10 63 7 32 185 49
<ul> <li>412</li> <li>413</li> <li>414</li> <li>415</li> <li>416</li> <li>417</li> <li>418</li> <li>419</li> </ul>	Protein lipidation of BACE. Biochemical Society Transactions, 2005, 33, 1091.         Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005, 33, 1033.         Novel and simple high-performance liquid chromatographic method for determination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 307-313.         Is Hypercholesterolemia a Risk Factor for Alzheimer's Disease?. Molecular Neurobiology, 2005, 31, 185-192.         Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. Journal of Neurochemistry, 2005, 92, 1386-1398.         Contributors to white matter damage in the frontal lobe in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2005, 31, 623-631.         Statins aC" a cure-all for the brain?. Nature Reviews Neuroscience, 2005, 6, 325-331.         Regulation of cholesterol and sphingomyelin metabolism by amyloid-Î <sup>2</sup> and presenilin. Nature Cell Biology, 2005, 7, 1118-1123.	<ul> <li>3.4</li> <li>3.4</li> <li>2.3</li> <li>4.0</li> <li>3.9</li> <li>3.2</li> <li>10.2</li> <li>10.3</li> </ul>	10 63 7 32 185 49 104 404

ARTICLE IF CITATIONS # Utilizing Pharmacologic Treatment Options to Improve Patient Care in Alzheimer's Disease. Journal of 421 1.4 0 the American Academy of Nurse Practitioners, 2005, 17, 1-12. Different localization in rat brain of the novel cytosolic ketone body-utilizing enzyme, 422 acetoacetyl-CoA synthetase, as compared to succinyl-CoA:3-oxoacid CoA-transferase. Biochimica Et 2.4 Biophysica Acta Gene Regulatory Mechanisms, 2005, 1729, 147-153. 423 Cholesterol in Alzheimer's disease. Lancet Neurology, The, 2005, 4, 841-852. 10.2 292 Cancer risk among statin users: A population-based cohort study. International Journal of Cancer, 424 5.1 254 2005, 114, 643-647. Lovastatin stimulates up-regulation of  $\hat{l} \pm 7$  nicotinic receptors in cultured neurons without 425 cholesterol dependency, a mechanism involving production of the 1±-form of secreted amyloid 2.9 24 precursor protein. Journal of Neuroscience Research, 2005, 82, 531-541. Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer's disease. Experimental Brain Research, 2005, 164, 205-214. 1.5 Alzheimer?s associated inflammation, potential drug targets and future therapies. Journal of Neural 428 2.8 92 Transmission, 2005, 112, 429-453. Influence of peroxisome proliferator-activated receptor 13 gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients. Journal óf Neural Transmission, 2005, 112, 429 2.8 1381-1389. 430 Statins: drugs for Alzheimer's disease?. Journal of Neural Transmission, 2005, 112, 1057-1071. 2.8 54 The Serotonin1A A Receptor: A Representative Member of the Serotonin Receptor Family. Cellular and 3.3 222 Molecular Neurobiology, 2005, 25, 553-580. Alzheimer's Diseaseâ€"A Dysfunction in Cholesterol and Lipid Metabolism. Cellular and Molecular 432 43 3.3 Neurobiology, 2005, 25, 475-483. The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst. Journal of 1.4 Negative Results in BioMedicine, 2005, 4, 3. Post-translational processing of beta-secretase in Alzheimer's disease. Proteomics, 2005, 5, 1533-1543. 434 2.2 23 Genes involved in Alzheimer's disease, a survey of possible candidates. Journal of Alzheimer's Disease, 2.6 2005, 7, 331-353. 436 Neurodegeneration., 2005, , 335-355. 0 A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders., 2005, , 222-226. 438 Alzheimer's disease: overview., 2005, , 416-432. 0 Relationship between Dementia and Nutrition-Related Factors and Disorders: An Overview. 439 1.5 International Journal for Vitamin and Nutrition Research, 2005, 75, 83-95.

ARTICLE IF CITATIONS # Treatment of Alzheimer's disease., 2005, , 459-470. 1 440 Cholesterol, Copper and Aβ in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment 441 1.4 38 Trial (ADCLT). Current Alzheimer Research, 2005, 2, 527-539. Do Statins Reduce Risk of Incident Dementia and Alzheimer Disease?<subtitle&gt;The Cache County 442 12.3 300 Study</subtitle&gt;. Archives of General Psychiatry, 2005, 62, 217. Cholesterol and Amyloid Î<sup>2</sup> Fibrillogenesis. , 2005, 38, 179-202. The Dualistic Nature of Immune Modulation In Alzheimers Disease: Lessons from the Transgenic 444 1.9 3 Models. Current Pharmaceutical Design, 2005, 11, 3335-3352. Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK. PLoS Medicine, 2005, 8.4 134 2, e18. Statins and cognitive function in the elderly. Neurology, 2005, 65, 1388-1394. 446 1.1 140 Association of active  $\hat{I}^3$ -secretase complex with lipid rafts. Journal of Lipid Research, 2005, 46, 904-912. 447 4.2 127 448 Serum cholesterol and risk of Alzheimer disease. Neurology, 2005, 65, 1045-1050. 140 1.1 <i>APOE</i> genotype, cholesterol level, lipid-lowering treatment, and dementia. Neurology, 2005, 64, 449 1.1 223 1531-1538. Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease. Archives of Neurology, 2005, 450 385 4.562,753. Statin Use and the Risk of Incident Dementia. Archives of Neurology, 2005, 62, 1047. 4.5 261 High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology, 2005, 452 1.1 346 64, 1689-1695. Lipid-Lowering Therapy for Elderly Patients at Risk for Coronary Events and Stroke. The American Heart Hospital Journal, 2005, 3, 256-262. 0.2 Drug Insight: using statins to treat neuroinflammatory disease. Nature Clinical Practice Neurology, 454 2.527 2005, 1, 106-112. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new 2.4 inhibitors?. Expert Opinion on Emerging Drugs, 2005, 10, 817-825. 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate Î2-Amyloid-Induced Microglial 456 3.6 164 Inflammatory Responses. Journal of Neuroscience, 2005, 25, 299-307. Apolipoprotein (apo) E4 enhances amyloid Î<sup>2</sup> peptide production in cultured neuronal cells: ApoE 458 structure as a potential therapeutic target. Proceedings of the National Academy of Sciences of the 7.1 242 United States of America, 2005, 102, 18700-18705.

#	Article	IF	CITATIONS
459	Statins Cause Intracellular Accumulation of Amyloid Precursor Protein, β-Secretase-cleaved Fragments, and Amyloid β-Peptide via an Isoprenoid-dependent Mechanism. Journal of Biological Chemistry, 2005, 280, 18755-18770.	3.4	133
460	Regulated expression of endothelial lipase by porcine brain capillary endothelial cells constituting the blood-brain barrier. Journal of Neurochemistry, 2005, 94, 109-119.	3.9	37
461	Translational Research on the Way to Effective Therapy for Alzheimer Disease. Archives of General Psychiatry, 2005, 62, 1186.	12.3	50
462	Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. Journal of Lipid Research, 2005, 46, 949-968.	4.2	157
463	No Genetic Association between ATP Binding Cassette Proteins and Japanese Sporadic Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 95-98.	1.5	2
464	Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1624-1629.	1.9	101
465	Cholesterol and apolipoprotein E in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 2005, 20, 91-96.	1.9	37
466	Treatment with statins in the acute phase of ischemic stroke. Expert Review of Neurotherapeutics, 2005, 5, 211-221.	2.8	21
467	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 256-265.	1.5	86
468	Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics. CNS and Neurological Disorders, 2005, 4, 553-567.	4.3	9
469	Mechanisms of Statin-mediated Inhibition of Small G-protein Function. Journal of Biological Chemistry, 2005, 280, 34202-34209.	3.4	205
471	Estatinas y enfermedad de Alzheimer: ¿son concluyentes los estudios actuales?. ClÃnica E Investigación En Arteriosclerosis, 2005, 17, 2-6.	0.8	0
472	Cholesterol and Alzheimer's Disease: Statins, Cholesterol Depletion in APP Processing and Aβ Generation. , 2005, 38, 365-380.		17
473	Effects of statins on microglia. Journal of Neuroscience Research, 2005, 82, 10-19.	2.9	45
474	Alzheimer disease is substantially preventable in the United States – review of risk factors, therapy, and the prospects for an expert software system. Medical Hypotheses, 2005, 64, 960-967.	1.5	23
475	The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. Journal of Clinical Investigation, 2005, 115, 1121-1129.	8.2	238
476	The link between cholesterol and Alzheimer's disease. World Journal of Biological Psychiatry, 2005, 6, 85-97.	2.6	54
477	Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies. Journal of Clinical Oncology, 2005, 23, 8606-8612.	1.6	214

#	Article	IF	CITATIONS
478	Chronic Administration of Statins Alters Multiple Gene Expression Patterns in Mouse Cerebral Cortex. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 786-793.	2.5	179
479	ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. Neurobiology of Disease, 2005, 18, 119-125.	4.4	109
480	Association between acyl-coenzyme A: cholesterol acyltransferase gene and risk for Alzheimer's disease in Chinese. Neuroscience Letters, 2005, 388, 17-20.	2.1	15
481	Cholesterol depletion inhibits the degradation of amyloid β-peptide in rat pheochromocytoma (PC12) cells. Neuroscience Letters, 2005, 391, 71-75.	2.1	8
482	Amyloid beta peptide-induced cholinergic fibres loss in the cerebral cortex of the rat is modified by diet high in lipids and by age. Journal of Chemical Neuroanatomy, 2005, 29, 31-48.	2.1	21
483	High-cholesterol diets impair short–term retention of memory in alloxan-induced diabetic mice, but not acquisition of memory nor retention of memory in prediabetic mice. Life Sciences, 2005, 77, 481-495.	4.3	28
484	Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women. Maturitas, 2005, 50, 312-320.	2.4	4
485	Lovastatin-induced PC-12 cell differentiation is associated with RhoA/RhoA kinase pathway inactivation. Molecular and Cellular Neurosciences, 2005, 29, 591-602.	2.2	18
486	Statins lower the risk of developing Alzheimer's disease by limiting lipid raft endocytosis and decreasing the neuronal spread of Herpes simplex virus type 1. Medical Hypotheses, 2005, 64, 53-58.	1.5	22
487	Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid β-infused rats relates to the decreases of amyloid β and cholesterol levels in detergent-insoluble membrane fractions. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1738, 91-98.	2.4	109
488	Statins downregulate myeloperoxidase gene expression in macrophages. Biochemical and Biophysical Research Communications, 2005, 331, 442-451.	2.1	86
489	Response to "The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes― Contemporary Clinical Trials, 2005, 26, 417-418.	1.8	0
490	Molecular biology and genetics of Alzheimer's disease. Comptes Rendus - Biologies, 2005, 328, 119-130.	0.2	163
491	Molecularly targeted agents: Their promise as cancer chemopreventive interventions. European Journal of Cancer, 2005, 41, 2003-2015.	2.8	28
492	Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. Parkinsonism and Related Disorders, 2005, 11, 81-84.	2.2	37
493	HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration?. Survey of Ophthalmology, 2005, 50, 194-206.	4.0	52
494	Developmental origins of aging in brain and blood vessels: an overview. Neurobiology of Aging, 2005, 26, 281-291.	3.1	64
495	Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice. Neurobiology of Aging, 2005, 26, 309-316.	3.1	40

#	Article	IF	Citations
496	Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiology of Aging, 2005, 26, 383-389.	3.1	187
497	Small hippocampal size in cognitively normal subjects with coronary artery disease. Neurobiology of Aging, 2005, 26, 865-871.	3.1	32
498	Genetic association of low density lipoprotein receptor and Alzheimer's disease. Neurobiology of Aging, 2005, 26, 1-7.	3.1	44
499	Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiology of Aging, 2005, 26, 355-361.	3.1	148
500	Cholesterol homeostasis in neurons and glial cells. Seminars in Cell and Developmental Biology, 2005, 16, 193-212.	5.0	184
501	Statin therapy in the treatment of Alzheimer disease: what is the rationale?. American Journal of Medicine, 2005, 118, 48-53.	1.5	41
502	Neuroinflammation: a potential therapeutic target. Expert Opinion on Therapeutic Targets, 2005, 9, 887-900.	3.4	97
503	Optimal lipids, statins, and dementia: Reply. Journal of the American College of Cardiology, 2005, 45, 964-965.	2.8	3
504	Optimal lipids, statins, and dementia. Journal of the American College of Cardiology, 2005, 45, 963-964.	2.8	6
505	The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 1425-1433.	2.8	248
506	A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. Journal of the Neurological Sciences, 2005, 229-230, 147-150.	0.6	14
507	PLEIOTROPIC EFFECTS OF STATINS. Annual Review of Pharmacology and Toxicology, 2005, 45, 89-118.	9.4	1,574
508	Pathophysiology of Alzheimer's Disease. Neuroimaging Clinics of North America, 2005, 15, 727-753.	1.0	68
509	Guidelines for the Treatment of Alzheimer??s Disease from the Italian Association of Psychogeriatrics. Drugs and Aging, 2005, 22, 1???26.	2.7	44
510	Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies. Reviews in the Neurosciences, 2005, 16, 181-212.	2.9	74
511	The Non-Amyloidogenic Pathway: Structure and Function of $\hat{I}\pm$ -Secretases. , 2005, 38, 105-127.		169
512	Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. Aging Clinical and Experimental Research, 2006, 18, 144-148.	2.9	17
513	Biological Markers of Age-Related Memory Deficits. CNS Drugs, 2006, 20, 153-166.	5.9	111

28

		REPORT	
# 514	ARTICLE Association of diagnosis of ischaemic heart disease, diabetes mellitus and heart failure with cognitive function in the elderly population. European Journal of General Practice, 2006, 12, 114-119.	IF 2.0	CITATIONS
515	Diabetes mellitus and dementia. Diabetes and Metabolism, 2006, 32, 403-414.	2.9	231
516	Alzheimer's disease. Lancet, The, 2006, 368, 387-403.	13.7	3,074
517	Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease. Expert Review of Neurotherapeutics, 2006, 6, 683-693.	2.8	20
519	Trace amounts of copper induce neurotoxicity in the cholesterol-fed mice through apoptosis. FEBS Letters, 2006, 580, 6730-6740.	2.8	52
520	Statin use and the risk of Alzheimer's disease: The MIRAGE Study. , 2006, 2, 96-103.		48
521	Commentary on "Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.― Atorvastatin's effect in Alzheimer's dementia (LEADe) study. , 2006, 2, 282-283.		1
522	The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. Journal of Neuroinflammation, 2006, 3, 30.	7.2	195
523	Statins of Different Brain Penetrability Differentially Affect CSF PLTP Activity. Dementia and Geriatric Cognitive Disorders, 2006, 22, 392-398.	1.5	56
524	The involvement of lipid rafts in Alzheimer's disease (Review). Molecular Membrane Biology, 2006, 23, 111-122.	2.0	182
525	Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials. Journal of Clinical Oncology, 2006, 24, 4808-4817.	1.6	154
526	Effects of lipids and aging on the neurotoxicity and neuronal loss caused by intracerebral injections of the amyloid-β peptide in the rat. Experimental Neurology, 2006, 197, 41-55.	4.1	20
527	Amyloid excess in Alzheimer's disease: What is cholesterol to be blamed for?. FEBS Letters, 2006, 580, 5525-5532.	2.8	67
528	Circulating biomarkers of cognitive decline and dementia. Clinica Chimica Acta, 2006, 364, 91-112.	1.1	124
529	Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. International Journal of Biochemistry and Cell Biology, 2006, 38, 1314-1329.	2.8	59
530	Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. Journal of Clinical Epidemiology, 2006, 59, 819-828.	5.0	115
531	Alzheimer-like Plaque Formation by Human Macrophages Is Reduced by Fibrillation Inhibitors and Lovastatin. Journal of Molecular Biology, 2006, 360, 251-257.	4.2	38
532	Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Medical Hypotheses, 2006, 67, 251-269.	1.5	81

#	Article	IF	CITATIONS
533	Toward prevention of alzheimers disease – Potential nutraceutical strategies for suppressing the production of amyloid beta peptides. Medical Hypotheses, 2006, 67, 682-697.	1.5	33
534	Human apoB overexpression and a high-cholesterol diet differently modify the brain APP metabolism in the transgenic mouse model of atherosclerosis. Neurochemistry International, 2006, 49, 393-400.	3.8	34
535	Influence of cholesterol and lovastatin on $\hat{I}\pm$ -form of secreted amyloid precursor protein and expression of $\hat{I}\pm7$ nicotinic receptor on astrocytes. Neurochemistry International, 2006, 49, 459-465.	3.8	27
536	Influence of lysosomal acid lipase polymorphisms on chromosome 10 on the risk of Alzheimer's disease and cholesterol metabolism. Neuroscience Letters, 2006, 402, 262-266.	2.1	11
537	PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease. Neuroscience Letters, 2006, 408, 57-61.	2.1	21
538	Hippocampal atrophy in the healthy is initially linear and independent of age. Neurobiology of Aging, 2006, 27, 1385-1394.	3.1	13
539	Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiology of Aging, 2006, 27, 1632-1643.	3.1	86
540	The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends in Neurosciences, 2006, 29, 518-527.	8.6	329
543	Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease. Cardiovascular & Hematological Disorders Drug Targets, 2006, 6, 21-34.	0.7	26
545	Statins inhibit the dimerization of $\hat{l}^2$ -secretase via both isoprenoid- and cholesterol-mediated mechanisms. Biochemical Journal, 2006, 399, 205-214.	3.7	45
546	Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. Journal of Alzheimer's Disease, 2006, 10, 399-406.	2.6	97
547	La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease. Neuroradiology Journal, 2006, 19, 453-474.	1.2	12
548	LR11/SorLA Expression Is Reduced in Sporadic Alzheimer Disease but not in Familial Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 866-872.	1.7	131
549	Lovastatin Modulates Increased Cholesterol and Oxysterol Levels and Has a Neuroprotective Effect on Rat Hippocampal Neurons After Kainate Injury. Journal of Neuropathology and Experimental Neurology, 2006, 65, 652-663.	1.7	56
550	Involvement of Oxidative Stress in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 631-641.	1.7	484
551	Lipid metabolism in Alzheimer's and Parkinson's disease. Future Lipidology, 2006, 1, 441-453.	0.5	14
552	Polymorphisms of the cholesterol 24-hydroxylase (CYP46A1) gene and the risk of Alzheimer's disease in a Chinese population. International Psychogeriatrics, 2006, 18, 37-45.	1.0	24
553	The Prevalence of Alzheimer Neuropathologic Lesions Is Similar in Blacks and Whites. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1143-1148.	1.7	26

		CITATION REPORT		
#	Article		IF	CITATIONS
554	Medications and Diet. Alzheimer Disease and Associated Disorders, 2006, 20, S89-S96		1.3	13
555	High-Dose Statin Treatment Does Not Alter Plasma Marker for Brain Cholesterol Metal Patients With Moderately Elevated Plasma Cholesterol Levels. Journal of Clinical Pharm 46, 812-816.	oolism in acology, 2006,	2.0	43
557	Cholesterol Depletion Reduces the Internalization of β-Amyloid Peptide in SH-SY5Y Ce Science and Technology, 2006, 11, 447-451.	lls*. Tsinghua	6.1	1
558	The 3-hydroxy-3-methylglutaryl co-enzymeâ€∱A reductase inhibitor pravastatin enhand outgrowth in hippocampal neurons. Journal of Neurochemistry, 2006, 97, 716-723.	es neurite	3.9	64
559	The effects of ABCA1 on cholesterol efflux and Aβ levels <i>in vitro</i> and <i>in vivo</i> Neurochemistry, 2006, 98, 792-800.	:/i>. Journal of	3.9	101
560	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and the Journal of Neurochemistry, 2006, 97, 1700-1725.	apeutics.	3.9	206
561	The Cellular Biochemistry of Cholesterol and Statins: Insights into the Pathophysiology of Alzheimer's Disease. CNS Neuroscience & Therapeutics, 2004, 10, 127-146.	<sup>,</sup> and Therapy	4.0	48
562	Relation between vascular risk factors and cognition at age 75. Acta Neurologica Scan 114, 84-90.	dinavica, 2006,	2.1	28
563	Role of cholesterol in amyloid cascade: cholesterol-dependent modulation of tau phos and mitochondrial function. Acta Neurologica Scandinavica, 2006, 114, 21-26.	phorylation	2.1	25
564	Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Act Scandinavica, 2006, 114, 63-70.	a Neurologica	2.1	91
565	Epidemiological and clinical trials evidence about a preventive role for statins in Alzhei Acta Neurologica Scandinavica, 2006, 114, 71-77.	ner's disease.	2.1	100
566	Effect of statins on beta-amyloid metabolism in humans: potential importance for the senile plaques in Alzheimer's disease. Acta Neurologica Scandinavica, 2006, 114, 87-9.	development of 2.	2.1	14
567	Cholesterol, statins and tau. Acta Neurologica Scandinavica, 2006, 114, 93-101.		2.1	20
568	The role of pleiotropic effects of statins in dementia. Acta Neurologica Scandinavica, 2	006, 114, 115-118.	2.1	15
569	Statins and bone metabolism. Oral Diseases, 2006, 12, 85-101.		3.0	92
570	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factor Alzheimer's disease and cardiovascular disease. Molecular Psychiatry, 2006, 11, 721-7	s for 36.	7.9	334
571	Cholesterol Distribution, Not Total Levels, Correlate With Altered Amyloid Precursor Pr Processing in Statin-Treated Mice. NeuroMolecular Medicine, 2006, 8, 319-328.	otein	3.4	52
572	NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeut Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 151-170.	ic Implications.	22.4	346

#	Article	IF	CITATIONS
573	Is the LDL Receptor Involved in Cortical Amyloid Protein Clearance?. Neurochemical Research, 2006, 31, 839-847.	3.3	15
574	Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease. Journal of Neural Transmission, 2006, 113, 231-238.	2.8	9
575	In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis, 2006, 9, 59-65.	7.2	34
576	"Brain Screen". Journal of Neurology, 2006, 253, 307-315.	3.6	11
577	Effect of pravastatin on plasma sterols and oxysterols in men. European Journal of Clinical Pharmacology, 2006, 62, 9-14.	1.9	29
578	Effects of atorvastatin on higher functions. European Journal of Clinical Pharmacology, 2006, 62, 259-265.	1.9	46
579	Lipid-lowering drugs. Cellular and Molecular Life Sciences, 2006, 63, 1165-1178.	5.4	174
580	Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: Bridging Niemann–Pick disease type C and Alzheimer's disease. Cellular Signalling, 2006, 18, 1844-1853.	3.6	61
581	Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Experimental Gerontology, 2006, 41, 220-224.	2.8	18
582	Cholesterol-enriched diet affects spatial learning and synaptic function in hippocampal synapses. Brain Research, 2006, 1103, 88-98.	2.2	43
583	Lipid metabolism in cognitive decline and dementia. Brain Research Reviews, 2006, 51, 275-292.	9.0	165
584	Cholesterol and Alzheimer's disease—is there a relation?. Mechanisms of Ageing and Development, 2006, 127, 138-147.	4.6	86
585	Isoprenoids and Alzheimer's disease: A complex relationship. Neurobiology of Disease, 2006, 22, 209-222.	4.4	72
586	Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant Aβ in plasma. Neurobiology of Disease, 2006, 24, 114-127.	4.4	112
587	Simvastatin enhances learning and memory independent of amyloid load in mice. Annals of Neurology, 2006, 60, 729-739.	5.3	138
588	Interventions for heart disease and their effects on Alzheimer's disease. Neurological Research, 2006, 28, 630-636.	1.3	33
589	Cardiac risk factors and potential treatments in Alzheimer's disease. Neurological Research, 2006, 28, 595-604.	1.3	44
590	Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease. International Journal of Molecular Medicine, 2006, 17, 791.	4.0	7

		Citation Report	
#	Article	IF	CITATIONS
591	Therapeutic options in Alzheimer's disease. Expert Review of Neurotherapeutics, 2006, 6, 897-910.	2.8	41
592	Statins: Are They All the Same?. Current Drug Therapy, 2006, 1, 157-172.	0.3	0
593	Therapeutic Perspectives in Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2006, 1, 119-127.	0.9	25
594	Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline?. Postgraduate Medical Journal, 2006, 82, 101-105.	1.8	49
595	Roles of Cholesterol and Lipids in the Etiopathogenesis of Alzheimer's Disease. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-17.	3.0	47
596	Candidate Susceptibility Genes in Alzheimers Disease Are at High Risk for Being Forgotten - They Dont Give Peace of Mind Current Drug Metabolism, 2006, 7, 273-293.	1.2	12
597	Brain Inflammation, Cholesterol, and Clutamate as Interconnected Participants in the Pathology of Alzheimers Disease. Current Pharmaceutical Design, 2006, 12, 719-738.	1.9	29
599	Mechanisms for Cellular Cholesterol Transport: Defects and Human Disease. Physiological Reviews, 2006, 86, 1237-1261.	28.8	185
600	Simvastatin-Induced Decline in Cognition. Annals of Pharmacotherapy, 2006, 40, 1880-1883.	1.9	43
601	Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1146-1152.	2.5	128
602	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of Psychopharmacology, 2006, 20, 732-755.	4.0	145
603	The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 233-239.	1.9	74
604	Intron 2 (T/C) CYP46 Polymorphism Is Associated with Alzheimer's Disease in Chinese Patients. Dementia and Geriatric Cognitive Disorders, 2006, 22, 399-404.	1.5	32
605	Causes and Diagnosis of Alzheimers Disease: A Proteomics Approach. Current Proteomics, 2006, 3, 81-112.	0.3	2
606	Hematologic Risk Factors of Vascular Disease and Their Relation to Dementia. Dementia and Geriatric Cognitive Disorders, 2006, 21, 335-352.	1.5	21
607	Can statins put the brakes on Alzheimer's disease?. Expert Opinion on Investigational Drugs, 2006, 15, 1479-1485.	4.1	24
608	Therapeutic approaches to Alzheimer's disease. Brain, 2006, 129, 2840-2855.	7.6	310
609	The Lipoprotein Receptor LR11 Regulates Amyloid β Production and Amyloid Precursor Protein Traffic in Endosomal Compartments. Journal of Neuroscience, 2006, 26, 1596-1603.	3.6	253

#	Δρτιςι ε	IF	CITATIONS
" 610	Regulation of Steady-state β-Amyloid Levels in the Brain by Neprilysin and Endothelin-converting Enzyme but Not Angiotensin-converting Enzyme. Journal of Biological Chemistry, 2006, 281,	3.4	177
	30471-30478.		
611	Retinal Degenerations. , 2007, , .		7
612	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	2.8	41
613	Liver X Receptor-Mediated Gene Regulation and Cholesterol Homeostasis in Brain: Relevance to Alzheimers Disease Therapeutics. Current Alzheimer Research, 2007, 4, 179-184.	1.4	65
614	Role of LXR and ABCA1 in the Pathogenesis of Alzheimers Disease -Implications for a New Therapeutic Approach. Current Alzheimer Research, 2007, 4, 171-178.	1.4	50
615	The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease. Current Genomics, 2007, 8, 509-530.	1.6	82
616	Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology, 2007, 69, 878-885.	1.1	212
617	Statins prevent cholinesterase inhibitor blockade of sympathetic α7-nAChR-mediated currents in rat superior cervical ganglion neurons. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1737-H1744.	3.2	24
618	The Therapeutic Potential of Statins in Neurological Disorders. Current Medicinal Chemistry, 2007, 14, 103-112.	2.4	58
619	Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications. Current Pharmaceutical Design, 2007, 13, 3622-3636.	1.9	87
620	Association of statin use with cognitive decline in elderly African Americans. Neurology, 2007, 69, 1873-1880.	1.1	69
621	High dietary cholesterol facilitates classical conditioning of the rabbit's nictitating membrane response. Nutritional Neuroscience, 2007, 10, 31-43.	3.1	17
622	Statin-Like Drugs for the Treatment of Brain Cholesterol Loss in Alzheimers Disease. Current Drug Safety, 2007, 2, 173-176.	0.6	6
623	New treatment options for vascular dementia. Aging Health, 2007, 3, 209-222.	0.3	3
624	Cardiovascular Risk Factors for Alzheimer's Disease. The American Journal of Geriatric Cardiology, 2007, 16, 143-149.	0.6	128
625	Prevention of Alzheimer's disease. International Review of Psychiatry, 2007, 19, 693-706.	2.8	30
626	Characterization of the Lipid Profile in Dementia and Depression in the Elderly. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 138-144.	2.3	35
627	Chapter 2 Alzheimer's Disease. Blue Books of Neurology, 2007, , 33-58.	0.1	2

#	Article	IF	CITATIONS
628	Prospects for Antioxidant Therapy in Mild Cognitive Impairment and Alzheimer's Disease. , 2007, , 451-466.		2
630	Prevention and Treatment of Dementia or Alzheimer's Disease by Statins: A Meta-Analysis. Dementia and Geriatric Cognitive Disorders, 2007, 23, 194-201.	1.5	82
631	Lipid-Lowering Agents and the Risk of Cognitive Impairment That Does Not Meet Criteria for Dementia, in Relation to Apolipoprotein E Status. Neuroepidemiology, 2007, 29, 201-207.	2.3	14
632	Clinical Trials of Amyloid-Based Therapies for Alzheimer's Disease. CNS Spectrums, 2007, 12, 7-10.	1.2	4
633	Alzheimer's Disease: <i>Progress in the Development of Anti-amyloid Disease-Modifying Therapies</i> . CNS Spectrums, 2007, 12, 113-123.	1.2	26
634	Pharmacotherapy of Alzheimer Disease. Canadian Journal of Psychiatry, 2007, 52, 620-629.	1.9	30
635	Regulation of the lipidation of Î <sup>2</sup> -secretase by statins. Biochemical Society Transactions, 2007, 35, 577-582.	3.4	14
636	Cholesterol-Lowering Drugs And Alzheimer'S Disease. Future Lipidology, 2007, 2, 423-432.	0.5	18
637	Primary Prevention and Delay of Onset of AD/Dementia. Canadian Journal of Neurological Sciences, 2007, 34, S84-S89.	0.5	13
638	Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-β proteins. Seminars in Cell and Developmental Biology, 2007, 18, 638-648.	5.0	52
639	Increased cholesterol in Aβ-positive nerve terminals from Alzheimer's disease cortex. Neurobiology of Aging, 2007, 28, 8-17.	3.1	94
640	Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease. Neurobiology of Aging, 2007, 28, 856-862.	3.1	69
641	Genetic risk profiles for Alzheimer's disease: Integration of APOE genotype and variants that up-regulate inflammation. Neurobiology of Aging, 2007, 28, 1637-1643.	3.1	67
642	The HMC-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-β1–42 in the rat hippocampus in vivo. Neuropharmacology, 2007, 52, 136-145.	4.1	60
643	Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by Aβ1–42. Neuropharmacology, 2007, 53, 222-231.	4.1	45
644	The cell cycle hypothesis of Alzheimer's disease: Suggestions for drug development. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 503-508.	3.8	51
645	Amyloid beta-protein and lipid metabolism. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 1991-2001.	2.6	38
646	Lipid–protein interactions, regulation and dysfunction of brain cholesterol. Biochemical and Biophysical Research Communications, 2007, 354, 627-633.	2.1	68

#	Article	IF	Citations
647	Amyloid beta as a regulator of lipid homeostasis. Trends in Molecular Medicine, 2007, 13, 337-344.	6.7	72
648	Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochemistry International, 2007, 50, 12-38.	3.8	132
649	Effects of statins on α7 nicotinic receptor, cholinesterase and α-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochemistry International, 2007, 50, 800-806.	3.8	26
650	Lovastatin protects human neurons against Aβ-induced toxicity and causes activation of β-catenin–TCF/LEF signaling. Neuroscience Letters, 2007, 412, 211-216.	2.1	46
651	LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus. Neuroscience Research, 2007, 59, 251-256.	1.9	36
652	The effect of statin on the aortic gene expression profiling. International Journal of Cardiology, 2007, 114, 71-77.	1.7	16
653	Links Between Amyloid and Tau Biology in Alzheimer's Disease and Their Cholinergic Aspects. , 2007, , 597-656.		2
656	Gender differences in dementia risk factors. Gender Medicine, 2007, 4, 120-129.	1.4	156
657	Effects of Statins on Cognitive Function in Patients with Alzheimer???s Disease in Galantamine Clinical Trials. Drugs and Aging, 2007, 24, 57-61.	2.7	25
658	Atorvastatin. Drugs, 2007, 67, 55-62.	10.9	15
659	evaluating clinical research. , 2007, , .		0
660	Statins Reduce Amyloid-β Production through Inhibition of Protein Isoprenylation. Journal of Biological Chemistry, 2007, 282, 26832-26844.	3.4	156
661	Mechanisms of Disease: new therapeutic strategies for Alzheimer's disease—targeting APP processing in lipid rafts. Nature Clinical Practice Neurology, 2007, 3, 374-382.	2.5	86
662	Effect of HMG-CoA Reductase Inhibitors on ??-Amyloid Peptide Levels. CNS Drugs, 2007, 21, 449-462.	5.9	53
663	Dementia syndromes: evaluation and treatment. Expert Review of Neurotherapeutics, 2007, 7, 407-422.	2.8	82
664	Cholesterol synthesis inhibitors protect against platelet-activating factor-induced neuronal damage. Journal of Neuroinflammation, 2007, 4, 5.	7.2	17
665	Simvastatin Suppresses Self-Renewal of Mouse Embryonic Stem Cells by Inhibiting RhoA Geranylgeranylation. Stem Cells, 2007, 25, 1654-1663.	3.2	52
666	Role of HMG-CoA Reductase Inhibitors in Neurological Disorders. Drugs, 2007, 67, 2111-2120.	10.9	34
#	Article	IF	CITATIONS
-----	---	----------------------	----------------
667	The road to load late-onset Alzheimer's disease and a possible way to block it. Expert Opinion on Therapeutic Targets, 2007, 11, 1257-1260.	3.4	11
669	1. 神çμŒé~域 (ã,¢ãƒ«ãƒ"ãƒã,₿ƒžãƒ¼ç−ã®å^†åæ™çš"æ²»ç™,). Japanese Journal of Clinical Pharmacology a	an <b>d Ti</b> herap	peuttics, 2007
670	Alzheimer's disease prevention – The emerging role of lipids and diet. Oleagineux Corps Gras Lipides, 2007, 14, 182-185.	0.2	1
671	Molecular genetics of Alzheimer's disease and other adult-onset dementias. , 0, , 439-453.		0
672	A novel intronic polymorphism of <i>ABCA1</i> gene reveals risk for sporadic Alzheimer's disease in Chinese. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 1007-1013.	1.7	26
673	ApoER2 expression increases AÎ <sup>2</sup> production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of Î <sup>3</sup> -secretase activity. Molecular Neurodegeneration, 2007, 2, 14.	10.8	66
674	Expression profiling in APP23 mouse brain: inhibition of AÎ <sup>2</sup> amyloidosis and inflammation in response to LXR agonist treatment. Molecular Neurodegeneration, 2007, 2, 20.	10.8	74
675	The Alzheimer's disease Beta-secretase enzyme, BACE1. Molecular Neurodegeneration, 2007, 2, 22.	10.8	386
676	Cognitive dysfunction associated with metabolic syndrome. Obesity Reviews, 2007, 8, 409-418.	6.5	71
677	EFFECT OF AMLODIPINE, A CALCIUM CHANNEL ANTAGONIST, ON CHOLESTEROL LEVELS IN THE CEREBRAL CORTEX AND HIPPOCAMPUS OF OBESE AND HYPERTENSIVE SHR.Cg-Leprcp/NDmcr RATS. Clinical and Experimental Pharmacology and Physiology, 2007, 34, S35-S36.	1.9	0
678	Long-term cognitive benefits of donepezil in Alzheimer?s disease: A retrospective comparison between 1994?1999 and 2000?2004. Geriatrics and Gerontology International, 2007, 7, 41-47.	1.5	11
679	Effects of human apolipoprotein E isoforms on the amyloid βâ€protein concentration and lipid composition in brain lowâ€density membrane domains. Journal of Neurochemistry, 2007, 101, 949-958.	3.9	7
680	A specific inhibitor of cholesterol biosynthesis, BM15.766, reduces the expression of ?-secretase and the production of amyloid-?in vitro. Journal of Neurochemistry, 2007, 102, 1276-1291.	3.9	11
681	Oxysterols, cholesterol homeostasis, and Alzheimer disease. Journal of Neurochemistry, 2007, 102, 1727-1737.	3.9	159
682	Alzheimer's disease: the lipid connection. Journal of Neurochemistry, 2007, 103, 159-170.	3.9	178
683	Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology, 2007, 14, e1-26.	3.3	499
684	Vascular risk factors and white matter hyperintensities in patients with amnestic mild cognitive impairment. Acta Neurologica Scandinavica, 2007, 115, 419-424.	2.1	14
685	Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Medicine, 2007, 5, 20.	5.5	334

#	Article	IF	CITATIONS
686	Polymorphisms of cholesterol metabolism genes CYP46 and ABCA1 and the risk of sporadic Alzheimer's disease in Chinese. Brain Research, 2007, 1147, 34-38.	2.2	41
687	Altered cholesterol metabolism in APP695-transfected neuroblastoma cells. Brain Research, 2007, 1152, 209-214.	2.2	6
688	The Inflammation Hypothesis and Its Potential Relevance to Statin Therapy. American Journal of Cardiology, 2007, 99, 732-738.	1.6	108
689	Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins. Journal of Cellular and Molecular Medicine, 2007, 11, 383-392.	3.6	119
690	Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. Journal of Cellular and Molecular Medicine, 2007, 11, 1227-1238.	3.6	123
691	Prevention of stroke and dementia by statin therapy: Experimental and clinical evidence of their pleiotropic effects. , 2007, 113, 378-393.		65
692	Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiology of Disease, 2007, 26, 273-281.	4.4	109
693	Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets. Journal of Neuroimmunology, 2007, 184, 17-26.	2.3	42
694	Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. Annals of the New York Academy of Sciences, 2007, 1097, 215-224.	3.8	27
695	Alzheimer Disease—No Target for Statin Treatment. A Mini Review. Neurochemical Research, 2007, 32, 695-706.	3.3	24
696	Alzheimer's Disease and Cholesterol: The Fat Connection. Neurochemical Research, 2007, 32, 739-750.	3.3	75
697	The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics, 2007, 8, 189-193.	1.4	39
698	Statins and dementia. Current Atherosclerosis Reports, 2007, 9, 154-161.	4.8	29
699	Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 46-51.	0.9	7
700	Plasma 24S Hydroxycholesterol Response to Statins in Alzheimer's Disease Patients: Effects of Gender, CYP46, and ApoE Polymorphisms. Journal of Molecular Neuroscience, 2007, 33, 51-55.	2.3	16
701	Mevalonate pathway: A review of clinical and therapeutical implications. Clinical Biochemistry, 2007, 40, 575-584.	1.9	471
702	Statins—Treatment Option for Central Nervous System Autoimmune Disease?. Neurotherapeutics, 2007, 4, 693-700.	4.4	21
703	Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 231-236.	1.6	4

#	Article	IF	CITATIONS
704	Substrate specificity of Î <sup>3</sup> -secretase and other intramembrane proteases. Cellular and Molecular Life Sciences, 2008, 65, 1311-1334.	5.4	267
705	Red mold rice extract represses amyloid beta peptide-induced neurotoxicity via potent synergism of anti-inflammatory and antioxidative effect. Applied Microbiology and Biotechnology, 2008, 79, 829-841.	3.6	59
707	Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with betaâ€amyloid peptide(1â€42) and fed a highâ€cholesterol diet. Journal of Neuroscience Research, 2008, 86, 183-193.	2.9	31
708	PPARÎ <sup>3</sup> Agonists as Therapeutics for the Treatment of Alzheimer's Disease. Neurotherapeutics, 2008, 5, 481-489.	4.4	254
709	Green tea catechins prevent cognitive deficits caused by Aβ1–40 in rats. Journal of Nutritional Biochemistry, 2008, 19, 619-626.	4.2	121
710	Diseases of protein aggregation and the hunt for potential pharmacological agents. Biotechnology Journal, 2008, 3, 165-192.	3.5	40
711	Atorvastatin attenuates mitochondrial toxinâ€induced striatal degeneration, with decreasing iNOS/câ€jun levels and activating ERK/Akt pathways. Journal of Neurochemistry, 2008, 104, 1190-1200.	3.9	29
712	Statins reduce neuronal αâ€synuclein aggregation in <i>in vitro</i> models of Parkinson's disease. Journal of Neurochemistry, 2008, 105, 1656-1667.	3.9	147
713	Lovastatin inhibits amyloid precursor protein (APP) β leavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. Journal of Neurochemistry, 2008, 105, 1536-1549.	3.9	37
714	High cholesterolâ€induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. Journal of Neurochemistry, 2008, 106, 475-485.	3.9	304
715	Docosahexaenoic acid disrupts <i>in vitro</i> amyloid β <sub>1â€40</sub> fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. Journal of Neurochemistry, 2008, 107, 1634-1646.	3.9	76
716	CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk. Brain Research, 2008, 1232, 1-6.	2.2	26
717	Fatty acids, lipid metabolism and Alzheimer pathology. European Journal of Pharmacology, 2008, 585, 176-196.	3.5	94
718	Seladinâ€1/DHCR24 protects neuroblastoma cells against Aβ toxicity by increasing membrane cholesterol content. Journal of Cellular and Molecular Medicine, 2008, 12, 1990-2002.	3.6	64
719	Cholesterol retention in Alzheimer's brain is responsible for high β- and γ-secretase activities and Aβ production. Neurobiology of Disease, 2008, 29, 422-437.	4.4	239
720	The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. Journal of the Neurological Sciences, 2008, 271, 87-90.	0.6	31
721	Point: Lipoproteins are significant factors in Alzheimer's disease: Dementia is impacted by blood plasma lipoproteins. Journal of Clinical Lipidology, 2008, 2, 391-393.	1.5	1
722	Early diagnosis and treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2008, 8, 769-780.	2.8	24

#	Article	IF	CITATIONS
724	Variation in NPC1, the gene encoding Niemann–Pick C1, a protein involved in intracellular cholesterol transport, is associated with Alzheimer disease and/or aging in the Polish population. Neuroscience Letters, 2008, 447, 153-157.	2.1	29
725	Cardiovascular risk factors and dementia. American Journal of Geriatric Pharmacotherapy, 2008, 6, 100-118.	3.0	183
726	Enhanced soluble CD40 ligand and Alzheimer's disease: Evidence of a possible pathogenetic role. Neurobiology of Aging, 2008, 29, 348-356.	3.1	35
727	Mechanisms of AÎ <sup>2</sup> mediated neurodegeneration in Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2008, 40, 181-198.	2.8	220
728	Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie, 2008, 90, 426-436.	2.6	101
729	Current approaches in the treatment of Alzheimer's disease. Biomedicine and Pharmacotherapy, 2008, 62, 199-207.	5.6	139
730	Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. Experimental Neurology, 2008, 212, 407-414.	4.1	104
731	Investigating the potential neuroprotective effects of statins on DNA damage in mouse striatum. Food and Chemical Toxicology, 2008, 46, 3186-3192.	3.6	9
732	Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neurolmage, 2008, 40, 1214-1221.	4.2	30
733	Diseaseâ€modifying therapies in Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 65-79.	0.8	132
734	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. Alzheimer's and Dementia, 2008, 4, 145-153.	0.8	56
735	Commentary on "The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics― , 2008, 4, 174-175.		0
737	Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2008, 16, 883-892.	1.2	108
738	Preventing Alzheimer's Disease. CNS Drugs, 2008, 22, 887-902.	5.9	16
739	Statin Adverse Effects. American Journal of Cardiovascular Drugs, 2008, 8, 373-418.	2.2	564
740	Pathophysiology of Neuronal Energy Crisis in Alzheimer's Disease. Neurodegenerative Diseases, 2008, 5, 126-132.	1.4	116
741	Alzheimer's disease: epidemiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 195-205.	1.8	18
742	Perspectives of Alzheimer's disease treatments. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 273-290.	1.8	2

#	Article	IF	CITATIONS
743	Independent Inhibition of Alzheimer Disease β- and γ-Secretase Cleavage by Lowered Cholesterol Levels. Journal of Biological Chemistry, 2008, 283, 11302-11311.	3.4	110
744	Direct and Potent Regulation of γ-Secretase by Its Lipid Microenvironment. Journal of Biological Chemistry, 2008, 283, 22529-22540.	3.4	240
745	Cognitive Performance and Plasma Levels of Homocysteine, Vitamin B <sub>12</sub> , Folate and Lipids in Patients with Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 384-390.	1.5	38
746	Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology, 2008, 71, 344-350.	1.1	221
747	ACAT as a Drug Target for Alzheimer's Disease. Neurodegenerative Diseases, 2008, 5, 212-214.	1.4	42
748	Genetic aspects of Alzheimer disease. Genetics in Medicine, 2008, 10, 231-239.	2.4	232
749	Emerging and potential therapies for Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2008, 12, 693-704.	3.4	27
750	Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology, 2008, 70, 1795-1802.	1.1	182
751	Geranylgeranyl pyrophosphate stimulates γâ€secretase to increase the generation of Aβ and APP TFγ. FASEB Journal, 2008, 22, 47-54.	0.5	54
752	A Pivotal Role for Interleukin-4 in Atorvastatin-associated Neuroprotection in Rat Brain. Journal of Biological Chemistry, 2008, 283, 1808-1817.	3.4	78
753	Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. , 2007, , 1-24.		5
754	BACE1 Structure and Function in Health and Alzheimers Disease. Current Alzheimer Research, 2008, 5, 100-120.	1.4	87
755	Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort. Current Alzheimer Research, 2008, 5, 416-421.	1.4	106
756	Disorders of Lipid Metabolism. Fundamental and Clinical Cardiology, 2008, , 159-178.	0.0	1
757	PPARÎ <sup>3</sup> Agonists for the Treatment of Alzheimer's Disease. , 2007, , 81-106.		0
758	Lipids as Key Players in Alzheimer Disease - Alterations in Metabolism and Genetics. Current Alzheimer Research, 2008, 5, 4-14.	1.4	16
759	Statin-Induced Heme Oxygenase-1 Increases NF-κB Activation and Oxygen Radical Production in Cultured Neuronal Cells Exposed to Lipopolysaccharide. Toxicological Sciences, 2008, 102, 150-159.	3.1	25
760	Vascular factors and prevention of dementia. International Review of Psychiatry, 2008, 20, 344-356.	2.8	39

#	ARTICLE HMG-CoA Reductase Inhibitor Simvastatin Inhibits Cell Cycle Progression at the G <sub>1</sub> /S	IF	CITATIONS
761	Checkpoint in Immortalized Lymphocytes from Alzheimer's Disease Patients Independently of Cholesterol-Lowering Effects. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 352-359.	2.5	30
762	Treatment of Vascular Dementia: The Route of Prevention. European Neurology, 2008, 60, 217-223.	1.4	26
763	Estrogens and Alzheimer's Disease: Is Cholesterol a Link?. Endocrinology, 2008, 149, 4253-4255.	2.8	3
764	Non-cholinergic drug development for Alzheimer's disease. Expert Opinion on Drug Discovery, 2008, 3, 745-760.	5.0	4
765	Potential therapeutic role of statins in neurological disorders. Expert Review of Neurotherapeutics, 2008, 8, 827-837.	2.8	21
766	Beyond Cholesterol: Statin Benefits in Alzheimer's Disease. , 2007, , 53-80.		1
767	Simvastatin-Induced Heme Oxygenase-1 Increases Apoptosis of Neuro 2A Cells in Response to Glucose Deprivation. Toxicological Sciences, 2008, 101, 112-121.	3.1	37
769	Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 13, 187-197.	2.6	88
770	Prevention of amyloid β-induced memory impairment by fluvastatin, associated with the decrease in amyloid β accumulation and oxidative stressin amyloid β injection mouse model. International Journal of Molecular Medicine, 2008, , .	4.0	16
771	Cognitive Impairment and Diabetes. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2008, 2, 218-223.	0.6	0
772	Recent Advances in Liver X Receptor Biology and Chemistry. Current Topics in Medicinal Chemistry, 2008, 8, 781-791.	2.1	34
773	Cholesterol lowering and beyond: role of statins in Alzheimer's disease. Aging Health, 2008, 4, 171-180.	0.3	3
774	The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Therapeutics and Clinical Risk Management, 2008, Volume 4, 605-615.	2.0	103
775	Comparison of the Mini Mental State Examination and depressive symptoms between high cardiovascular risk and healthy community elderly groups. Dementia E Neuropsychologia, 2008, 2, 294-299.	0.8	2
776	Vascular risk factors, cognitve decline, and dementia. Vascular Health and Risk Management, 2008, Volume 4, 363-381.	2.3	264
777	Aberrant Expression of Myeloperoxidase in Astrocytes Promotes Phospholipid Oxidation and Memory Deficits in a Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2009, 284, 3158-3169.	3.4	102
778	Mitochondrial Cholesterol Loading Exacerbates Amyloid Î <sup>2</sup> Peptide-Induced Inflammation and Neurotoxicity. Journal of Neuroscience, 2009, 29, 6394-6405.	3.6	134
779	Statins. , 2009, , 253-280.		5

#	Article	IF	CITATIONS
780	Molecular Pathogenesis of Alzheimer's Disease: Reductionist versus Expansionist Approaches. International Journal of Molecular Sciences, 2009, 10, 1386-1406.	4.1	43
781	An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads. Intervirology, 2009, 52, 43-48.	2.8	77
782	Long-Term Statin Therapy and CSF Cholesterol Levels: Implications for Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2009, 27, 519-524.	1.5	24
783	Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. Journal of Lipid Research, 2009, 50, 2095-2102.	4.2	32
784	Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. Brain, 2009, 132, 1346-1354.	7.6	16
785	Statins Reduce the Neurofibrillary Tangle Burden in a Mouse Model of Tauopathy. Journal of Neuropathology and Experimental Neurology, 2009, 68, 314-325.	1.7	79
786	Anti-Amyloid Treatments in Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2009, 4, 143-148.	0.9	10
787	Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry. Current Medicinal Chemistry, 2009, 16, 685-705.	2.4	121
788	Effects of Achieving an LDL-Cholesterol Level of <70 mg/dL Compared With the Goal of <100 mg/dL Using Simvastatin or Atorvastatin on Cognitive Processes in High-Risk Diabetic Patients. , 2009, 19, 271-279.		1
789	Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiology of Disease, 2009, 35, 406-414.	4.4	112
790	Statinâ€Associated Adverse Cognitive Effects: Survey Results from 171 Patients. Pharmacotherapy, 2009, 29, 800-811.	2.6	166
791	RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism. Journal of Cellular and Molecular Medicine, 2009, 13, 589-598.	3.6	34
792	Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk. Brain Research, 2009, 1280, 166-171.	2.2	38
793	The influence of age on the association between cholesterol and cognitive function. Experimental Gerontology, 2009, 44, 112-122.	2.8	63
794	Translational medicine perspective in development of disease modifying therapies for Alzheimer's disease: biomarkers to buy down the risk. Drug Development Research, 2009, 70, 60-69.	2.9	2
795	Mitochondria, cholesterol and amyloid β peptide: a dangerous trio in Alzheimer disease. Journal of Bioenergetics and Biomembranes, 2009, 41, 417-423.	2.3	50
796	Novel N-terminal Cleavage of APP Precludes AÎ <sup>2</sup> Generation in ACAT-Defective AC29 Cells. Journal of Molecular Neuroscience, 2009, 37, 6-15.	2.3	23
797	Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: Possible role of P-glycoprotein inhibition by lovastatin. Archives of Pharmacal Research, 2009, 32, 1447-1452.	6.3	8

	CITATION R	EPORT	
#	ARTICLE Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular	IF	CITATIONS
798	and other progressive inflammatory and degenerative diseases. BMC Medical Genomics, 2009, 2, 2.	1.5	421
799	SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells. Nature Cell Biology, 2009, 11, 143-153.	10.3	237
800	The Role of Neuroimmunomodulation in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1153, 240-246.	3.8	206
801	Activityâ€Regulated Cytoskeletonâ€Associated Protein in Rodent Brain is Downâ€Regulated by High Fat Diet <i>in vivo</i> and by 27â€Hydroxycholesterol <i>in vitro</i> . Brain Pathology, 2009, 19, 69-80.	4.1	78
802	Treatment Practices of Mild Cognitive Impairment in California Alzheimer's Disease Centers. Journal of the American Geriatrics Society, 2009, 57, 686-690.	2.6	26
803	Haptoglobin binds apolipoprotein E and influences cholesterol esterification in the cerebrospinal Fluid. Journal of Neurochemistry, 2009, 110, 255-263.	3.9	41
804	Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. Journal of Neurochemistry, 2009, 111, 1275-1308.	3.9	211
805	Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein E. BioFactors, 2009, 35, 239-248.	5.4	94
806	What do the statin trials tell us?. Clinical Cardiology, 2009, 24, 3-7.	1.8	8
807	Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 13-17.	1.9	319
808	Current Hypotheses and Research Milestones in Alzheimer's Disease. , 2009, , .		4
809	The essential role of lipids in Alzheimer's disease. Biochimie, 2009, 91, 804-809.	2.6	54
810	Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. Seminars in Cell and Developmental Biology, 2009, 20, 191-200.	5.0	105
811	Oxysterols and neurodegenerative diseases. Molecular Aspects of Medicine, 2009, 30, 171-179.	6.4	250
812	Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis) Tj ETQq0 0 C Medicine, 2009, 30, 153-170.	) rgBT /Ove 6.4	rlock 10 Tf 5 242
813	Drug development for Alzheimer's disease: Where are we now and where are we headed?. American Journal of Geriatric Pharmacotherapy, 2009, 7, 167-185.	3.0	124
814	Mitochondrial Glutathione, a Key Survival Antioxidant. Antioxidants and Redox Signaling, 2009, 11, 2685-2700.	5.4	777
815	Cholesterol, lipoproteins, and cognitive impairment. Journal of Clinical Lipidology, 2009, 3, 368-371.	1.5	2

ARTICLE IF CITATIONS # Chapter 3 Cerebrovascular and Cardiovascular Pathology in Alzheimer's Disease. International Review 816 2.0 70 of Neurobiology, 2009, 84, 35-48. Common Pathological Processes and Transcriptional Pathways in Alzheimer's Disease and Type 2 2.6 49 Diabetes. Journal of Alzheimer's Disease, 2009, 16, 787-808. 818 Statins for the prevention of dementia., 2009, CD003160. 131 Platelet α- and β-secretase activities: A preliminary study in normal human subjects. Platelets, 2009, 20, 29-34. Neuroprotective Effects of Statins in an In Vitro Model of Alzheimer's Disease. Journal of Alzheimer's 820 2.6 21 Disease, 2009, 17, 503-517. Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 405-409. 2.1 Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting 822 2.9 47  $\hat{l}^2$ -amyloid and tau protein. Aging Clinical and Experimental Research, 2009, 21, 386-406. Mild cholesterol depletion reduces amyloidâ $\in \hat{i}^2$  production by impairing APP trafficking to the cell 60 surface. Journal of Neurochemistry, 2009, 110, 220-230. Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum. CNS Neuroscience 824 3.9 129 and Therapeutics, 2009, 15, 358-374. Increased Atherogenic Lipoproteins are Associated With Cognitive Impairment. Alzheimer Disease and 1.3 Associated Disorders, 2009, 23, 11-17. Use of Statins and Risk of Hospitalization With Dementia. Alzheimer Disease and Associated Disorders, 826 1.3 22 2009, 23, 18-22. On Cholesterol Levels and Statins in Cognitive Decline and Alzheimer Disease. Alzheimer Disease and 1.3 Associated Disorders, 2009, 23, 303-305. Neuropathology in the Adult Changes in Thought Study: A Review. Journal of Alzheimer's Disease, 828 2.6 65 2009, 18, 703-711. Treatment of latent stage Alzheimer's disease with statins?. Aging Health, 2009, 5, 29-32. 0.3 Immunomodulator Activity of 3-Hydroxy-3-Methilglutaryl-CoA Inhibitors. Cardiovascular and 831 1.0 34 Hematological Agents in Medicinal Chemistry, 2009, 7, 279-294. Nutrition and dementia. Nursing and Residential Care, 2010, 12, 112-116. 0.1 Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and 833 2.6 106 Parkinson's Diseases. Journal of Alzheimer's Disease, 2010, 20, S127-S141. 834 Lipids and Cognition. Journal of Alzheimer's Disease, 2010, 20, 737-747.

#	Article	IF	CITATIONS
835	Long-Term Statin Therapy is Associated with Better Episodic Memory in Aged Familial Hypercholesterolemia Patients in Comparison with Population Controls. Journal of Alzheimer's Disease, 2010, 21, 611-617.	2.6	16
836	Changes in Cognition and Amyloid-Î <sup>2</sup> Processing with Long Term Cholesterol Reduction using Atorvastatin in Aged Dogs. Journal of Alzheimer's Disease, 2010, 22, 135-150.	2.6	34
837	Serum lipids and gender affect trajectories of cognitive function in late life. Clinical Lipidology, 2010, 5, 481-487.	0.4	0
838	Current Treatment and Recent Clinical Research in Alzheimer's Disease. Mount Sinai Journal of Medicine, 2010, 77, 3-16.	1.9	68
839	Chapter 1. The Amyloid Hypothesis of Alzheimer's Disease and Prospects for Therapeutics. RSC Drug Discovery Series, 2010, , 3-18.	0.3	0
840	Alzheimer Disease. Disease-a-Month, 2010, 56, 484-546.	1.1	391
841	Anticholinergic drug use and risk for dementia: target for dementia prevention. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 111-115.	3.2	99
842	Targeting inflammation to slow or delay functional decline: where are we?. Biogerontology, 2010, 11, 603-614.	3.9	29
843	豆蔻酰化的å⁻Œä,™æ°¨é…,的蛋白激酶C 的媕物在é~¿å°"茨海é»~ç—…èfžåžè¿‡ç¨‹ä,çš"ä½	20 <b>ez.'9'.</b> Net	ıra≊∉ience Bu
844	Effects of prednisolone on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. Archives of Pharmacal Research, 2010, 33, 1395-1400.	6.3	2
845	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. Journal of Cardiology, 2010, 55, 155-162.	1.9	29
846	Oxidative stress impairs learning and memory in apoE knockout mice. Pharmacology Biochemistry and Behavior, 2010, 96, 181-186.	2.9	39
847	The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends in Genetics, 2010, 26, 84-93.	6.7	122
848	Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 1217-1224.	1.0	90
849	Pravastatin treatment causes a shift in the balance of hippocampal neurotransmitter binding densities towards inhibition. Brain Research, 2010, 1316, 17-26.	2.2	3
850	Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. Brain Research, 2010, 1318, 167-177.	2.2	46
851	A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations. Brain Research, 2010, 1344, 185-191.	2.2	14
852	Simvastatin enhances immune responses to AÎ <sup>2</sup> vaccination and attenuates vaccination-induced behavioral alterations. Brain Research, 2010, 1356, 102-111.	2.2	7

#	Article	IF	CITATIONS
854	The effects of cholesterol on learning and memory. Neuroscience and Biobehavioral Reviews, 2010, 34, 1366-1379.	6.1	87
855	Quercetin activates AMPâ€activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterolâ€induced neurotoxicity. Journal of Pathology, 2010, 222, 199-212.	4.5	159
856	Neuriteâ€ <b>i</b> ike structures induced by mevalonate pathway blockade are due to the stability of cell adhesion foci and are enhanced by the presence of APP. Journal of Neurochemistry, 2010, 114, 832-842.	3.9	5
857	Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. Journal of Neurochemistry, 2010, 115, 153-167.	3.9	76
858	Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. Journal of Neurochemistry, 2010, 115, 551-562.	3.9	63
859	Prevention of dementia by ACE inhibitors and angiotensin receptor blockers - potential but not proven. International Journal of Clinical Practice, 2010, 64, 1595-1598.	1.7	3
860	Upregulation of the αâ€secretase ADAM10â€f–â€frisk or reason for hope?. FEBS Journal, 2010, 277, 1585-15	9 <b>6.</b> 7	69
861	Vascular Pharmacotherapy and Dementia. Current Vascular Pharmacology, 2010, 8, 44-50.	1.7	3
862	Statin Users Without an APOE-ε4 Allele have Increased Insulin Resistance. Journal of Alzheimer's Disease, 2010, 19, 1149-1153.	2.6	7
863	Cholesterol in Alzheimer's Disease and other Amyloidogenic Disorders. Sub-Cellular Biochemistry, 2010, 51, 47-75.	2.4	37
864	Cognitive decline: the relevance of diabetes, hyperlipidaemia and hypertension. British Journal of Diabetes and Vascular Disease, 2010, 10, 115-122.	0.6	18
865	Oxysterols in biological systems: The gastrointestinal tract, liver, vascular wall and central nervous system. Free Radical Research, 2010, 44, 47-73.	3.3	38
866	Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. Journal of Lipid Research, 2010, 51, 598-605.	4.2	95
867	Secretory phospholipase A2 type III enhances î±-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity. Journal of Lipid Research, 2010, 51, 957-966.	4.2	30
868	Statins Promote the Degradation of Extracellular Amyloid β-Peptide by Microglia via Stimulation of Exosome-associated Insulin-degrading Enzyme (IDE) Secretion. Journal of Biological Chemistry, 2010, 285, 37405-37414.	3.4	176
869	Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. Alzheimer Disease and Associated Disorders, 2010, 24, 220-226.	1.3	57
870	The Role of Statins in the Prevention and Treatment of Alzheimer's Disease. Journal of Pharmacy Technology, 2010, 26, 276-284.	1.0	1
871	Amyloid-β as a Modulator of Synaptic Plasticity. Journal of Alzheimer's Disease, 2010, 22, 741-763.	2.6	225

	CHARLON	ICLPORT	
#	Article	IF	CITATIONS
872	Cholesterol, Lipids, Amyloid Beta, and Alzheimers. Current Alzheimer Research, 2010, 7, 262-270.	1.4	36
873	Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ: British Medical Journal, 2010, 340, b5465-b5465.	2.3	393
874	Statins and the Squalene Synthase Inhibitor Zaragozic Acid Stimulate the Non-Amyloidogenic Pathway of Amyloid-β Protein Precursor Processing by Suppression of Cholesterol Synthesis. Journal of Alzheimer's Disease, 2010, 20, 1215-1231.	2.6	41
875	Amyloidosis and Neurodegenerative Diseases: Current Treatments and New Pharmacological Options. Pharmacology, 2010, 85, 1-17.	2.2	25
876	Vascular risk factors and dementia. British Journal of Cardiac Nursing, 2010, 5, 240-246.	0.1	6
877	Can Statins Prevent or Help Treat Alzheimer's Disease?. Journal of Alzheimer's Disease, 2010, 20, 925-933.	2.6	64
878	Genetic Factors in Alzheimer Disease and Dementia. , 2010, , 681-697.		0
879	Niemann–Pick type C cells show cholesterol dependent decrease of APP expression at the cell surface and its increased processing through the β-secretase pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 682-691.	3.8	30
880	A second class of nuclear receptors for oxysterols: Regulation of RORα and RORÎ <sup>3</sup> activity by 24S-hydroxycholesterol (cerebrosterol). Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 917-923.	2.4	114
881	Alterations of cholesterol precursor levels in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 945-950.	2.4	53
882	Intracellular cholesterol homeostasis and amyloid precursor protein processing. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 853-859.	2.4	32
883	Membrane rafts in Alzheimer's disease beta-amyloid production. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 860-867.	2.4	240
884	Brain cholesterol in normal and pathological aging. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 934-944.	2.4	131
885	ACAT inhibition and amyloid beta reduction. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 960-965.	2.4	56
886	Role of amyloid beta in lipid homeostasis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 966-974.	2.4	65
887	Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 831-838.	2.4	32
888	Lipids and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 747-749.	2.4	12
889	Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience, 2010, 166, 435-444.	2.3	68

#	Article	IF	CITATIONS
890	Alzheimer's disease: brain expression of a metabolic disorder?. Trends in Endocrinology and Metabolism, 2010, 21, 537-544.	7.1	39
891	Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. Journal of Pharmacy and Pharmacology, 2010, 63, 129-135.	2.4	10
892	Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease. Mount Sinai Journal of Medicine, 2010, 77, 82-102.	1.9	181
893	Statins improve visual field alterations related to hypercholesterolemia. Atherosclerosis, 2010, 209, 510-514.	0.8	4
894	Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. NeuroImage, 2010, 49, 169-176.	4.2	61
895	Cell cycle and Alzheimer's disease: studies in non-neuronal cells. Journal of Applied Biomedicine, 2010, 8, 121-130.	1.7	9
896	Reduction of Brain β-Amyloid (Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and Aβ Clearance. Journal of Biological Chemistry, 2010, 285, 22091-22102.	3.4	95
897	Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4. Alzheimer's Research and Therapy, 2010, 2, 31.	6.2	7
898	Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design. Alzheimer's Research and Therapy, 2011, 4, 3.	6.2	9
899	Investigational drugs for the treatment of AD: what can we learn from negative trials?. Alzheimer's Research and Therapy, 2011, 3, 14.	6.2	5
900	Simvastatin is the Statin that Most Efficiently Protects Against Kainate-Induced Excitotoxicity and Memory Impairment. Journal of Alzheimer's Disease, 2011, 24, 161-174.	2.6	62
901	Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. Molecular Diagnosis and Therapy, 2011, 15, 83-102.	3.8	25
902	Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action. Pharmacological Research, 2011, 63, 172-180.	7.1	86
903	γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C. Neurology, 2011, 76, 366-372.	1.1	62
904	Targeting liver X receptors in human health: deadlock or promising trail?. Expert Opinion on Therapeutic Targets, 2011, 15, 219-232.	3.4	73
907	Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacological Reports, 2011, 63, 1066-1073.	3.3	42
908	VI. Other Types of Cerebrovascular Disorders. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, S129-S144.	1.6	0
909	Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases. Experimental Neurology, 2011, 230, 27-34.	4.1	127

ARTICLE IF CITATIONS Atorvastatin and AÎ<sup>2</sup>(1–40): Not as Simple as Cholesterol Reduction in Brain and Relevance to Alzheimer 910 4.1 9 Disease. Experimental Neurology, 2011, 228, 15-18. Vascular Dementia and Vascular Cognitive Decline., 2011, , 252-267. Mild Cognitive Impairment and Dementia. Deutsches Ärzteblatt International, 2011, 108, 913 0.9 147 743-50. Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System. International Journal of Alzheimer's Disease, 2011, 2011, 1-34. Genetic Risk Factors: Their Function and Comorbidities in Alzheimer's Disease. International Journal 916 2.0 1 of Alzheimer's Disease, 2011, 2011, 1-2. Mechanisms of Amyloid-Beta Peptide Uptake by Neurons: The Role of Lipid Rafts and Lipid Raft-Associated Proteins. International Journal of Alzheimer's Disease, 2011, 2011, 1-11. Omega-3 polyunsaturated fatty acids in the brain: metabolism and neuroprotection. Frontiers in 918 3.0 78 Bioscience - Landmark, 2011, 16, 2653. Reduction of A by fluvastatin associates with altered levels of APP and of BACE1 and ADAM10 mRNA, independent of brain total cholesterol in rats. African Journal of Pharmacy and Pharmacology, 2011, 5, 0.3 1655-1660. Lipid Rafts: Linking Alzheimer's Amyloid- $\langle i \rangle$ <sup>2</sup>  $2 / i \rangle$  Production, Aggregation, and Toxicity at Neuronal 920 2.0 156 Membranes. International Journal of Alzheimer's Disease, 2011, 2011, 1-14. Function and Comorbidities of Apolipoprotein E in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-22. Current conceptions of the etiology and risk factors for Alzheimer's disease and their possible 922 0.0 0 implications on the design of dementia clinical trials. Clinical Investigation, 2011, 1, 1491-1503. Endolysosome Mechanisms Associated with Alzheimer's Disease-like Pathology in Rabbits Ingesting Cholesterol-Enriched Diet. Journal of Alzheimer's Disease, 2011, 22, 1289-1303. Berberine: A Potential Multipotent Natural Product to Combat Alzheimer's Disease. Molecules, 2011, 16, 924 3.8 142 6732-6740. Statins: The Role in the Treatment and Prevention of Alzheimer's Neurodegeneration. Journal of 2.6 Alzheimer's Disease, 2011, 27, 1-10. Nitric oxide involvement in consolidation, but not retrieval phase of cognitive performance enhanced 926 3.5 15 by atorvastatin in mice. European Journal of Pharmacology, 2011, 666, 122-130. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and 927 2.2 phosphorylated tau in aged APP mice. Brain Research, 2011, 1371, 161-170. Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: Involvement of 928 2.2 25 nitric oxide. Brain Research, 2011, 1386, 89-99. 929 HSV1 in Alzheimerâ $\in$ <sup>MS</sup> disease: Myth or reality?. Translational Neuroscience, 2011, 2, . 1.4

ARTICLE IF CITATIONS # Statins as Neuroprotectants: A Comparative In Vitro Study of Lipophilicity, Blood-Brain-Barrier Penetration, Lowering of Brain Cholesterol, and Decrease of Neuron Cell Death. Journal of 930 2.6 181 Alzheimer's Disease, 2011, 23, 307-318. Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. 3.1 Psychopharmacology, 2011, 216, 537-544. Red mold fermented products and Alzheimer's disease: a review. Applied Microbiology and 932 3.6 28 Biotechnology, 2011, 91, 461-469. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in Rats: Possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. Archives of Pharmacal Research, 2011, 34, 309-315. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: Possible role of cytochrome p450 3A4 and P-glycoprotein inhibition by 934 6.3 51 baicalein. Archives of Pharmacal Research, 2011, 34, 1965-1972. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. European Journal of Drug Metabolism 1.6 and Pharmacokinetics, 2011, 36, 175-182. Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's. 936 1.9 17 Journal of Applied Genetics, 2011, 52, 213-218. Neurovascular dysfunction, inflammation and endothelial activation: Implications for the 937 7.2 pathogenesis of Alzheimer's disease. Journal of Neuroinflammation, 2011, 8, 26. Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's 938 disease suggests a role for rs3846662 and HMGCR splicing in disease risk. Molecular 10.8 11 Neurodegeneration, 2011, 6, 62. Oxysterols as biomarkers in neurodegenerative diseases. Chemistry and Physics of Lipids, 2011, 164, 3.2 184 515-524. Therapeutic Interventions Targeting Beta Amyloid Pathogenesis in an Aging Dog Model. Current 940 17 2.9 Neuropharmacology, 2011, 9, 651-661. Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers 1.4 Disease. Current Alzheimer Research, 2011, 8, 434-442. The Fox and the Rabbitsâ€"Environmental Variables and Population Genetics (1) Replication Problems in Association Studies and the Untapped Power of GWAS (2) Vitamin A Deficiency, Herpes Simplex 942 1.5 8 Reactivation and Other Causes of Alzheimer's Disease. ISRN Neurology, 2011, 2011, 1-29. Cerebrospinal Fluid Levels of Soluble Amyloid Precursor Protein and Î<sup>2</sup>-Amyloid 42 in Patients with Multiple Sclerosis, Neuromyelitis Optica and Clinically Isolated Syndrome. Journal of International Medical Research, 2011, 39, 2402-2413. 943 1.0 16 Cholesterol Level and Statin Use in Alzheimer Disease. Archives of Neurology, 2011, 68, 1385. 944 4.5 166 Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases. 945 1.9 48 Current Pharmaceutical Design, 2011, 17, 230-245. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. 946 3.7 96 Journal of Epidemiology and Community Health, 2011, 65, 949-957. γ-Secretase, Apolipoprotein E and Cellular Cholesterol Metabolism. Current Alzheimer 947 1.4 Research, 2012, 9, 189-199.

#	Article	IF	CITATIONS
948	Dual Effects of Statins on Aß Metabolism: Upregulation of the Degradation of APP-CTF and Aß Clearance. Neurodegenerative Diseases, 2012, 10, 305-308.	1.4	12
949	Sterol Lipid Metabolism in Down Syndrome Revisited: Down Syndrome Is Associated with a Selective Reduction in Serum Brassicasterol Levels. Current Gerontology and Geriatrics Research, 2012, 2012, 1-11.	1.6	13
950	Adult Changes in Thought Study: Dementia is an Individually Varying Convergent Syndrome with Prevalent Clinically Silent Diseases that may be Modified by Some Commonly Used Therapeutics. Current Alzheimer Research, 2012, 9, 718-723.	1.4	51
951	Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer's Disease: A Pilot Study. Current Alzheimer Research, 2012, 9, 990-997.	1.4	27
952	The involvement of nitric oxide in the anti-seizure effect of acute atorvastatin treatment in mice. Neurological Research, 2012, 34, 847-853.	1.3	25
953	How Statins Could Be Evaluated Successfully in Clinical Trials for Alzheimer's Disease?. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 151-153.	1.9	5
954	Endothelin-Converting Enzymes and Related Metalloproteases in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S101-S110.	2.6	25
955	Statins for the primary prevention of cardiovascular disease in women?. Menopause, 2012, 19, 1287-1288.	2.0	2
956	Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 241-281.	2.6	51
957	Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Neurological Research, 2012, 34, 601-610.	1.3	42
958	Regulation of Cerebral Cholesterol Metabolism in Alzheimer Disease. Journal of Investigative Medicine, 2012, 60, 576-582.	1.6	30
959	Low-density lipoprotein receptor-related protein 1: A physiological $\hat{A^2}$ homeostatic mechanism with multiple therapeutic opportunities. , 2012, 136, 94-105.		99
960	Efficacy and Safety of Statins in Older Adults. Current Cardiovascular Risk Reports, 2012, 6, 372-379.	2.0	2
961	Cholesterol and Alzheimer's disease: A still poorly understood correlation. IUBMB Life, 2012, 64, 931-935.	3.4	40
962	Statins, Risk of Dementia, and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 436-444.	1.6	108
963	Atorvastatin stimulates neuroblastoma cells to induce neurite outgrowth by increasing cellular prion protein expression. Neuroscience Letters, 2012, 531, 114-119.	2.1	13
964	The effects of statins on mood: a review of the literature. European Journal of Cardiovascular Nursing, 2012, 11, 85-96.	0.9	38
965	Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. DMM Disease Models and Mechanisms, 2012, 5, 746-55.	2.4	254

#	Article	IF	CITATIONS
966	Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. Neuroscience, 2012, 202, 1-9.	2.3	58
967	Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms. Antioxidants and Redox Signaling, 2012, 16, 974-1031.	5.4	163
968	Upstream Transcription Factor 1 (USF1) Polymorphisms Associate with Alzheimer's Diseaseâ€related Neuropathological Lesions: Tampere Autopsy Study. Brain Pathology, 2012, 22, 765-775.	4.1	17
969	The Effect of HMG-CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study. American Journal of Geriatric Pharmacotherapy, 2012, 10, 296-302.	3.0	65
970	Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain. Journal of the Neurological Sciences, 2012, 322, 59-63.	0.6	30
971	Lipid Metabolism and Neuroinflammation in Alzheimer's Disease: A Role for Liver X Receptors. Endocrine Reviews, 2012, 33, 715-746.	20.1	67
972	Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer's Disease. Molecular Neurobiology, 2012, 46, 64-77.	4.0	43
973	A Review of the Major Vascular Risk Factors Related to Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 521-530.	2.6	77
974	Statins in Unconventional Secretion of Insulin-Degrading Enzyme and Degradation of the Amyloid-β Peptide. Neurodegenerative Diseases, 2012, 10, 309-312.	1.4	22
975	Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits. Journal of Neuroscience, 2012, 32, 4705-4715.	3.6	146
976	Restoration of dietary-fat induced blood–brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Lipids in Health and Disease, 2012, 11, 117.	3.0	47
977	Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference. PLoS Computational Biology, 2012, 8, e1002503.	3.2	674
978	4.5 Literatur. , 2012, , .		0
979	The Kynurenine Pathway. , 2012, , .		5
980	Peripheral cholesterol, metabolic disorders and Alzheimer's disease. Frontiers in Bioscience - Elite, 2012, E4, 181.	1.8	19
981	Accumulation of Exogenous Amyloid- <i>Beta</i> Peptide in Hippocampal Mitochondria Causes Their Dysfunction: A Protective Role for Melatonin. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-15.	4.0	59
982	Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer. Pharmacological Reviews, 2012, 64, 102-146.	16.0	370
983	Is Statin-Associated Cognitive Impairment Clinically Relevant? A Narrative Review and Clinical Recommendations. Annals of Pharmacotherapy, 2012, 46, 549-557.	1.9	100

#	Article	IF	CITATIONS
984	The role of APP proteolytic processing in lipid metabolism. Experimental Brain Research, 2012, 217, 365-375.	1.5	59
985	The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model. European Journal of Pharmacology, 2012, 674, 20-26.	3.5	14
986	Modulation of <i>inâ€∫vitro</i> activity of zymogenic and mature recombinant human βâ€secretase by dietary plants. FEBS Journal, 2012, 279, 1291-1305.	4.7	9
987	The link between altered cholesterol metabolism and Alzheimer's disease. Annals of the New York Academy of Sciences, 2012, 1259, 54-64.	3.8	108
988	Impairment of the ABCA1 and SR-BI-mediated cholesterol efflux pathways and HDL anti-inflammatory activity in Alzheimer's disease. Mechanisms of Ageing and Development, 2012, 133, 20-29.	4.6	37
989	Combined treatment of AÎ <sup>2</sup> immunization with statin in a mouse model of Alzheimer's disease. Journal of Neuroimmunology, 2012, 244, 70-83.	2.3	12
990	Selective liver X receptor modulators (SLiMs): What use in human health?. Molecular and Cellular Endocrinology, 2012, 351, 129-141.	3.2	102
991	The analytical determination of isoprenoid intermediates from the mevalonate pathway. Analytical and Bioanalytical Chemistry, 2012, 402, 671-685.	3.7	20
992	Statins Reduce Amyloid Î <sup>2</sup> -Peptide Production by Modulating Amyloid Precursor Protein Maturation and Phosphorylation Through a Cholesterol-Independent Mechanism in Cultured Neurons. Neurochemical Research, 2013, 38, 589-600.	3.3	20
993	Genetics of Alzheimer Disease. , 2013, , 1-20.		0
994	A canine model of human aging and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1384-1389.	3.8	98
995	Statins in the prevention of dementia and Alzheimer's disease: A metaâ€analysis of observational studies and an assessment of confounding. Pharmacoepidemiology and Drug Safety, 2013, 22, 345-358.	1.9	96
996	Substitution of membrane cholesterol with Î <sup>2</sup> -sitosterol promotes nonamyloidogenic cleavage of endogenous amyloid precursor protein. Neuroscience, 2013, 247, 227-233.	2.3	30
997	Analysis of the protein network of cholesterol homeostasis maintenance in a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2013, 8, P37.	10.8	0
998	Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs. International Journal of Neuroscience, 2013, 123, 521-525.	1.6	14
999	A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting Enzyme. Pharmacological Reviews, 2013, 65, 1-46.	16.0	240
1000	Intracerebral propagation of Alzheimer's disease: Strengthening evidence of a herpes simplex virus etiology. Alzheimer's and Dementia, 2013, 9, 169-175.	0.8	75
1002	Alzheimer's Disease, Cholesterol, and Statins: The Junctions of Important Metabolic Pathways. Angewandte Chemie - International Edition, 2013, 52, 1110-1121.	13.8	56

#	Article	IF	Citations
1003	CYP46A1 intron-2T/C polymorphism and Alzheimer's disease: An updated meta-analysis of 16 studies including 3960 cases and 3828 controls. Neuroscience Letters, 2013, 549, 18-23.	2.1	9
1004	Statins and Cognition: A Systematic Review and Meta-analysis of Short- and Long-term Cognitive Effects. Mayo Clinic Proceedings, 2013, 88, 1213-1221.	3.0	181
1005	Dyslipidemia and the Risk of Alzheimer's Disease. Current Atherosclerosis Reports, 2013, 15, 307.	4.8	134
1006	Role of Cholesterol in APP Metabolism and Its Significance in Alzheimer's Disease Pathogenesis. Molecular Neurobiology, 2013, 47, 37-63.	4.0	102
1007	Atorvastatin prevents cell damage via modulation of oxidative stress, glutamate uptake and glutamine synthetase activity in hippocampal slices subjected to oxygen/glucose deprivation. Neurochemistry International, 2013, 62, 948-955.	3.8	28
1008	Liver X receptors: Emerging therapeutic targets for Alzheimer's disease. Pharmacological Research, 2013, 72, 45-51.	7.1	50
1009	Brain Insulin Dysregulation: Implication for Neurological and Neuropsychiatric Disorders. Molecular Neurobiology, 2013, 47, 1045-1065.	4.0	93
1010	Association of statin use with risk of dementia: A metaâ€analysis of prospective cohort studies. Geriatrics and Gerontology International, 2013, 13, 817-824.	1.5	47
1011	Kynurenines and other novel therapeutic strategies in the treatment of dementia. Therapeutic Advances in Neurological Disorders, 2013, 6, 386-397.	3.5	19
1012	Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Journal of Alzheimer's Disease, 2013, 33, 547-658.	2.6	21
1013	The Impact of Cholesterol, DHA, and Sphingolipids on Alzheimer's Disease. BioMed Research International, 2013, 2013, 1-16.	1.9	64
1014	The Cache County Study on Memory in Aging: Factors affecting risk of Alzheimer's disease and its progression after onset. International Review of Psychiatry, 2013, 25, 673-685.	2.8	51
1015	Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. Journal of Lipid Research, 2013, 54, 3052-3061.	4.2	47
1016	Cholesterol homeostasis: a key to prevent or slow down neurodegeneration. Frontiers in Physiology, 2012, 3, 486.	2.8	62
1017	Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin. Korean Journal of Physiology and Pharmacology, 2013, 17, 245.	1.2	7
1018	ROLE OF STATINS IN THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION. Retina, 2013, 33, 414-422.	1.7	39
1019	Statins and Cognitive Function. Annals of Internal Medicine, 2013, 159, 688.	3.9	212
1020	A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. Neuropsychiatric Disease and Treatment. 2013. 9, 55.	2.2	14

#	Article	IF	CITATIONS
1021	Defensive Effect of Lansoprazole in Dementia of AD Type in Mice Exposed to Streptozotocin and Cholesterol Enriched Diet. PLoS ONE, 2013, 8, e70487.	2.5	32
1022	Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Frontiers in Aging Neuroscience, 2013, 5, 64.	3.4	53
1023	Emerging Therapeutic Strategies in Alzheimer's Disease. , 0, , .		1
1024	Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease. Clinical Interventions in Aging, 2013, 8, 103.	2.9	91
1025	Alzheimer Disease and Metabolism: Role of Cholesterol and Membrane Fluidity. , 0, , .		1
1026	Effects of Statins on Incident Dementia in Patients with Type 2 DM: A Population-Based Retrospective Cohort Study in Taiwan. PLoS ONE, 2014, 9, e88434.	2.5	25
1027	Prevention approaches in a preclinical canine model of Alzheimerââ,¬â,,¢s disease: benefits and challenges. Frontiers in Pharmacology, 2014, 5, 47.	3.5	32
1028	Glutathione and mitochondria. Frontiers in Pharmacology, 2014, 5, 151.	3.5	401
1029	Imaging of cerebrovascular pathology in animal models of Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 32.	3.4	71
1030	Possible modification of Alzheimerââ,¬â"¢s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Frontiers in Aging Neuroscience, 2014, 6, 71.	3.4	43
1031	Examination of the FDA Warning for Statins and Cognitive Dysfunction. Journal of Pharmacovigilance, 2014, 02, .	0.2	15
1032	Physiological Role of Amyloid Beta in Neural Cells: The Cellular Trophic Activity. , 0, , .		25
1033	Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry, 2014, 14, 348.	2.6	66
1034	Women with the Alzheimer's risk marker ApoE4 lose Aβ-specific CD4+ T cells 10–20 years before men. Translational Psychiatry, 2014, 4, e414-e414.	4.8	16
1035	Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives. , 2014, , 3-39.		5
1036	Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System. International Journal of Molecular Sciences, 2014, 15, 20607-20637.	4.1	133
1037	Cholesterol Balance in Prion Diseases and Alzheimer's Disease. Viruses, 2014, 6, 4505-4535.	3.3	28
1038	Cyclopamine Modulates Î <sup>3</sup> -Secretase-mediated Cleavage of Amyloid Precursor Protein by Altering Its Subcellular Trafficking and Lysosomal Degradation. Journal of Biological Chemistry, 2014, 289, 33258-33274.	3.4	11

#	Article	IF	CITATIONS
1039	Simvastatin Treatment Preserves Synaptic Plasticity in AβPPswe/PS1dE9 Mice. Journal of Alzheimer's Disease, 2014, 39, 315-329.	2.6	19
1040	Selective benefits of simvastatin in bitransgenic APPSwe,Ind/TGF-β1 mice. Neurobiology of Aging, 2014, 35, 203-212.	3.1	26
1041	Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease. Neurobiology of Aging, 2014, 35, S3-S10.	3.1	87
1042	Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets. Biochemical Pharmacology, 2014, 88, 605-616.	4.4	73
1043	Statins use and risk of depression: A systematic review and meta-analysis. Journal of Affective Disorders, 2014, 160, 62-67.	4.1	81
1044	Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. Acta Pharmacologica Sinica, 2014, 35, 716-726.	6.1	32
1045	Oxidative stress and its effect on cell functional activity in Alzheimer's disease. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2014, 8, 181-191.	0.4	3
1046	Endothelial progenitor cells in diabetic patients with myocardial infarction – Can statins improve their function?. European Journal of Pharmacology, 2014, 741, 25-36.	3.5	10
1047	Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial. Trials, 2014, 15, 202.	1.6	15
1048	Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Reports, 2014, 15, 1036-1052.	4.5	224
1049	Simvastatin Treatment Enhances NMDAR-Mediated Synaptic Transmission by Upregulating the Surface Distribution of the GluN2B Subunit. Cellular and Molecular Neurobiology, 2014, 34, 693-705.	3.3	22
1050	Cholesterol and metal ions in Alzheimer's disease. Chemical Society Reviews, 2014, 43, 6672-6682.	38.1	82
1051	Inhibiting Geranylgeranylation Increases Neurite Branching and Differentially Activates Cofilin in Cell Bodies and Growth Cones. Molecular Neurobiology, 2014, 50, 49-59.	4.0	13
1052	Dietary modulators of statin efficacy in cardiovascular disease and cognition. Molecular Aspects of Medicine, 2014, 38, 1-53.	6.4	13
1053	Statins in neurological disorders: An overview and update. Pharmacological Research, 2014, 88, 74-83.	7.1	65
1054	Bidirectional links between Alzheimer's disease and Niemann–Pick type C disease. Neurobiology of Disease, 2014, 72, 37-47.	4.4	68
1055	The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: It's time for reconciliation. Neurobiology of Disease, 2014, 62, 144-159.	4.4	109
1058	Statins induce insulin-degrading enzyme secretion from astrocytes via an autophagy-based unconventional secretory pathway. Molecular Neurodegeneration, 2015, 10, 56.	10.8	52

#	Article	IF	CITATIONS
1059	Lovastatin Differentially Affects Neuronal Cholesterol and Amyloidâ€ <i>β</i> Production <i>inÂvivo</i> and <i>inÂvitro</i> . CNS Neuroscience and Therapeutics, 2015, 21, 631-641.	3.9	15
1060	Cholesterolâ€induced astrocyte activation is associated with increased amyloid precursor protein expression and processing. Glia, 2015, 63, 2010-2022.	4.9	30
1061	The Mevalonate Pathway in Alzheimer's Disease — Cholesterol and Non-Sterol Isoprenoids. , 2015, , .		8
1062	Statins and memory loss: An Australian perspective. Australasian Medical Journal, 2015, 8, 73-79.	0.1	10
1063	Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. , 2015, 6, 282.		101
1064	Free Cholesterol — A Double-Edge Sword in Alzheimer Disease. , 0, , .		2
1065	Role of Liver X Receptor in AD Pathophysiology. PLoS ONE, 2015, 10, e0145467.	2.5	36
1066	Nonhuman Primate Models of Human Disease. , 2015, , 257-277.		1
1067	α-Synuclein-Induced Synapse Damage in Cultured Neurons Is Mediated by Cholesterol-Sensitive Activation of Cytoplasmic Phospholipase A2. Biomolecules, 2015, 5, 178-193.	4.0	25
1068	Statins and Cognitive Function: an Updated Review. Current Cardiology Reports, 2015, 17, 4.	2.9	16
1069	Investigation of the Memory Impairment in Rats Fed with Oxidized-Cholesterol-Rich Diet Employing Passive Avoidance Test. Drug Research, 2015, 65, 231-237.	1.7	8
1070	Statins and Reduction of Oxidative Stress in the Aged Brain. , 2015, , 753-760.		3
1071	Potential role of statins in the intracerebral hemorrhage and subarachnoid hemorrhage. Neurologia I Neurochirurgia Polska, 2015, 49, 322-328.	1.2	12
1072	Lipids in Amyloid-β Processing, Aggregation, and Toxicity. Advances in Experimental Medicine and Biology, 2015, 855, 67-94.	1.6	56
1073	Atorvastatin prevents AÎ <sup>2</sup> oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage. Acta Pharmacologica Sinica, 2015, 36, 553-564.	6.1	12
1074	Decreased prevalence of dementia associated with statins: a national populationâ€based study. European Journal of Neurology, 2015, 22, 912-918.	3.3	24
1075	Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-β1–40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems. Neurotoxicity Research, 2015, 28, 32-42.	2.7	25
1076	Statins enhance cognitive performance in object location test in albino Swiss mice: Involvement of beta-adrenoceptors. Physiology and Behavior, 2015, 143, 27-34.	2.1	9

		CITATION REPORT		
#			IE	
# 1078	Monascus-fermented monascin and ankaflavin improve the memory and learning ability in a l <sup>2</sup> -protein intracerebroventricular-infused rat via the suppression of Alzheimer's disease risk Journal of Functional Foods, 2015, 18, 387-399.	amyloid factors.	3.4	28
1079	Statins and the risk of dementia in patients with atrial fibrillation: A nationwide population- cohort study. International Journal of Cardiology, 2015, 196, 91-97.	based	1.7	31
1080	Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Poss of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. Pharmacological Reports, 44-51.	sible role 2015, 67,	3.3	14
1081	The Role of Cholesterol Metabolism in Alzheimer's Disease. Molecular Neurobiology, 20	015, 51, 947-965.	4.0	62
1082	Lower Risk of Alzheimer's Disease Mortality with Exercise, Statin, and Fruit Intake. Journal c Alzheimer's Disease, 2015, 44, 1121-1129.	f	2.6	19
1083	Impact on Cognitive Function—Are All Statins the Same?. Current Atherosclerosis Reports 466.	s, 2015, 17,	4.8	7
1084	HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's d cohorts study. Molecular Psychiatry, 2015, 20, 867-873.	isease in a three	7.9	51
1085	Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotection of n-3 PUFA in Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 123-134.	ve Effect	1.4	43
1086	Endocrine Risk Factors for Cognitive Impairment. Endocrinology and Metabolism, 2016, 31	, 185.	3.0	27
1087	Tocotrienol Affects Oxidative Stress, Cholesterol Homeostasis and the Amyloidogenic Path Neuroblastoma Cells: Consequences for Alzheimer's Disease. International Journal of M Sciences, 2016, 17, 1809.	way in olecular	4.1	35
1088	Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-CC pilot randomised controlled trial. Trials, 2016, 17, 370.	)G study): A	1.6	18
1089	Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Thre Anti-Inflammatory Pathway. CNS and Neurological Disorders - Drug Targets, 2016, 15, 80-8	bugh an 5.	1.4	8
1090	Simvastatin and atorvastatin facilitates amyloid βâ€protein degradation in extracellular spa increasing neprilysin secretion from astrocytes through activation of <scp>MAPK/E</scp> rl pathways. Glia, 2016, 64, 952-962.	aces by 21/2	4.9	60
1091	Effectiveness of atorvastatin in suppressing <i>MUC5AC</i> gene expression in human airvepithelial cells. International Forum of Allergy and Rhinology, 2016, 6, 1159-1166.	way	2.8	7
1092	Statins for the prevention of dementia. The Cochrane Library, 2016, 2016, CD003160.		2.8	212
1093	Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach. of the New York Academy of Sciences, 2016, 1367, 50-56.	Annals	3.8	37

1094	Inhibition of Cholesterol Biosynthesis Reduces γ-Secretase Activity and Amyloid-β Generation. Journal of Alzheimer's Disease, 2016, 51, 1057-1068.	2.6	22
1095	Alzheimer's Disease Risk Genes and Lipid Regulators. Journal of Alzheimer's Disease, 2016, 53, 15-29.	2.6	53

#	Article	IF	CITATIONS
1096	Risk factors for dementia diagnosis in German primary care practices. International Psychogeriatrics, 2016, 28, 1059-1065.	1.0	79
1097	Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis. Journal of Alzheimer's Disease, 2016, 51, 45-55.	2.6	63
1098	Could drugs inhibiting the mevalonate pathway also target cancer stem cells?. Drug Resistance Updates, 2016, 25, 13-25.	14.4	80
1099	Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy. Cellular and Molecular Neurobiology, 2016, 36, 219-232.	3.3	39
1100	Statins and Risk of Bleeding: An Analysis to Evaluate Possible Bias Due to Prevalent Users and Healthy User Aspects. American Journal of Epidemiology, 2016, 183, 930-936.	3.4	26
1101	Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology. Journal of Molecular Neuroscience, 2016, 58, 109-119.	2.3	10
1102	Neurochemical Aspects of Alzheimer Disease. , 2016, , 1-76.		1
1103	Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 695-712.	3.0	129
1105	Hypertension and Stroke. , 2016, , .		3
1106	Hepatic, gastric and intestinal firstâ€pass effects of vitexinâ€2â€2â€2â€4i>Oâ€rhamnoside in rats by ultraâ€highâ€performance liquid chromatography. Biomedical Chromatography, 2016, 30, 111-116.	1.7	6
1107	Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. Journal of the Neurological Sciences, 2016, 361, 256-271.	0.6	107
1108	Simvastatin enhances NMDA receptor GluN2B expression and phosphorylation of GluN2B and GluN2A through increased histone acetylation and Src signaling in hippocampal CA1 neurons. Neuropharmacology, 2016, 107, 411-421.	4.1	26
1109	Brain cortical cholesterol metabolism is highly affected by human APP overexpression in mice. Molecular and Cellular Neurosciences, 2016, 74, 34-41.	2.2	7
1110	Therapeutic Potentials of Curcumin for Alzheimer Disease. , 2016, , .		13
1111	Interpretation of mushroom as a common therapeutic agent for Alzheimer's disease and cardiovascular diseases. Critical Reviews in Biotechnology, 2016, 36, 1131-1142.	9.0	22
1112	Vascular Dementia and Cognitive Impairment. , 2016, , 253-267.e7.		0
1113	Potential of tocotrienols in the prevention and therapy of Alzheimer's disease. Journal of Nutritional Biochemistry, 2016, 31, 1-9.	4.2	33
1114	Regulation of Calcium-Independent Phospholipase A2 Expression by Adrenoceptors and Sterol Regulatory Element Binding Protein—Potential Crosstalk Between Sterol and Glycerophospholipid Mediators. Molecular Neurobiology, 2016, 53, 500-517.	4.0	4

#	Article	IF	CITATIONS
1115	Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 10.	6.2	145
1116	Blood cholesterol in late-life and cognitive decline: a longitudinal study of the Chinese elderly. Molecular Neurodegeneration, 2017, 12, 24.	10.8	87
1117	Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 69-87.	2.4	283
1118	Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. Journal of Lipid Research, 2017, 58, 2083-2101.	4.2	65
1119	Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer's disease via modulating the expression of miR-106b. Biomedicine and Pharmacotherapy, 2017, 92, 46-57.	5.6	89
1120	Four Decades of Research in Alzheimer's Disease (1975–2014): A Bibliometric and Scientometric Analysis. Journal of Alzheimer's Disease, 2017, 59, 763-783.	2.6	33
1121	Statins and Cognition in Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 661-667.	2.8	13
1122	Proteomic profiling of human intraschisis cavity fluid. Clinical Proteomics, 2017, 14, 13.	2.1	10
1123	Intensive LDL-cholesterol lowering therapy and neurocognitive function. , 2017, 170, 181-191.		55
1124	Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2017, 1, 125-157.	2.2	47
1125	Neurodegenerative Disorders. , 2017, , 1-16.		18
1126	Effects of ABCA1 R219K Polymorphism and Serum Lipid Profiles on Mild Cognitive Impairment in Type 2 Diabetes Mellitus. Frontiers in Aging Neuroscience, 2017, 9, 257.	3.4	10
1127	APP Function and Lipids: A Bidirectional Link. Frontiers in Molecular Neuroscience, 2017, 10, 63.	2.9	76
1128	Intracellular Cholesterol Trafficking and Impact in Neurodegeneration. Frontiers in Molecular Neuroscience, 2017, 10, 382.	2.9	103
1129	Contribution of Neural Membrane Phospholipids, Sphingolipids, and Cholesterol in the Pathogenesis of Alzheimer's Disease. , 2017, , 93-127.		0
1130	Screening for mild cognitive impairment in patients with cardiovascular risk factors. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2925-2934.	2.2	11
1131	Interaction between amyloidogenic proteins and biomembranes in protein misfolding diseases: Mechanisms, contributors, and therapy. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1876-1888.	2.6	20
1132	Systematic review of the efficacy of statins for the treatment of Alzheimer's disease. Clinical Medicine, 2018, 18, 54-61.	1.9	29

#	Article	IF	Citations
1133	CYP46A1 and the APOEε4 Allele Polymorphisms Correlate with the Risk of Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 8179-8187.	4.0	15
1134	Differences in statin associated neuroprotection corresponds with either decreased production of IL-11 <sup>2</sup> or TNF-1 <sup>±</sup> in an in vitro model of neuroinflammation-induced neurodegeneration. Toxicology and Applied Pharmacology, 2018, 344, 56-73.	2.8	36
1135	Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease. Critical Reviews in Biochemistry and Molecular Biology, 2018, 53, 279-310.	5.2	95
1136	Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 90-96.	2.3	21
1137	Risk Factors and Prevention in Alzheimer's Disease and Dementia. , 2018, , 93-112.		3
1138	Bioconversion of mevastatin to pravastatin by various microorganisms and its applications – A review. Biocatalysis and Agricultural Biotechnology, 2018, 13, 62-74.	3.1	9
1139	Connecting the brain cholesterol and renin–angiotensin systems: potential role of statins and <scp>RAS</scp> â€modifying medications in dementia. Journal of Internal Medicine, 2018, 284, 620-642.	6.0	30
1140	Statin Therapy and Cognitive Impairment: Benefit or Harm?. Rational Pharmacotherapy in Cardiology, 2018, 14, 529-536.	0.8	1
1141	Simvastatin Enhances Activity and Trafficking of α7 Nicotinic Acetylcholine Receptor in Hippocampal Neurons Through PKC and CaMKII Signaling Pathways. Frontiers in Pharmacology, 2018, 9, 362.	3.5	22
1142	The lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain. PLoS Biology, 2018, 16, e2006443.	5.6	75
1143	The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Translational Neurodegeneration, 2018, 7, 5.	8.0	147
1144	Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?. International Journal of Molecular Sciences, 2019, 20, 3858.	4.1	42
1145	Genetics, Ageing and Human Health. , 2019, , 193-209.		0
1146	Emerging roles for highâ€density lipoproteins in neurodegenerative disorders. BioFactors, 2019, 45, 725-739.	5.4	29
1147	Modulating Effect of Diet on Alzheimer's Disease. Diseases (Basel, Switzerland), 2019, 7, 12.	2.5	26
1148	Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of <i>APOB</i> . JAMA Neurology, 2019, 76, 809.	9.0	94
1150	Bioactive Lipids and the Gut-Brain Axis: Diet as a Modulator of Bioactivity and Diversity of Lipids in the Brain. Advances in Experimental Medicine and Biology, 2019, 1127, 147-168.	1.6	1
1151	Why Is Very High Cholesterol Content Beneficial for the Eye Lens but Negative for Other Organs?. Nutrients, 2019, 11, 1083.	4.1	26

#	Article	IF	Citations
1152	Association Between Statin Use and Risk of Dementia After a Concussion. JAMA Neurology, 2019, 76, 887.	9.0	34
1153	Unraveling the Paradox of Statins with Human Neurons: New Leads in Alzheimer's Disease. Cell Stem Cell, 2019, 24, 347-349.	11.1	12
1154	Biocatalyzed Synthesis of Statins: A Sustainable Strategy for the Preparation of Valuable Drugs. Catalysts, 2019, 9, 260.	3.5	36
1155	A Review and Hypothesized Model of the Mechanisms That Underpin the Relationship Between Inflammation and Cognition in the Elderly. Frontiers in Aging Neuroscience, 2019, 11, 56.	3.4	74
1156	Is Alzheimer's Disease Risk Modifiable?. Journal of Alzheimer's Disease, 2019, 67, 795-819.	2.6	73
1157	Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions. Journal of Alzheimer's Disease, 2019, 67, 923-930.	2.6	24
1158	Statins and the risk of bleeding in patients taking dabigatran. Acta Neurologica Scandinavica, 2019, 139, 455-461.	2.1	9
1159	Significant association of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) rs3846662 and sirtuin 1 (SIRT1) rs7895833 and apolipoprotein E (APOE) hypermethylation with mild cognitive impairment (MCI). Medicine (United States), 2019, 98, e16405.	1.0	3
1160	Statin therapy: does sex matter?. Menopause, 2019, 26, 1425-1435.	2.0	33
1161	Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. Progress in Neurobiology, 2019, 174, 53-89.	5.7	223
1162	Cholesterol and Dementia: A Long and Complicated Relationship. Current Aging Science, 2020, 13, 42-51.	1.2	22
1163	Statin use increased new-onset diabetes in hypercholesterolemic individuals: Data from the Korean National Health Insurance Service-National Health Screening Cohort database (NHIS-HEALS). Primary Care Diabetes, 2020, 14, 246-253.	1.8	13
1164	Effect of atorvastatin on Aβ1–42-induced alteration of SESN2, SIRT1, LC3II and TPP1 protein expressions in neuronal cell cultures. Journal of Pharmacy and Pharmacology, 2020, 72, 424-436.	2.4	18
1165	Effect of statins on amyloidosis in the rodent models of Alzheimer's disease: Evidence from the preclinical meta-analysis. Brain Research, 2020, 1749, 147115.	2.2	6
1166	From beta amyloid to altered proteostasis in Alzheimer's disease. Ageing Research Reviews, 2020, 64, 101126.	10.9	31
1167	The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins. International Journal of Molecular Sciences, 2020, 21, 8745.	4.1	42
1168	Quinovic Acid Impedes Cholesterol Dyshomeostasis, Oxidative Stress, and Neurodegeneration in an Amyloid-β-Induced Mouse Model. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-20.	4.0	15
1169	MAM and C99, key players in the pathogenesis of Alzheimer's disease. International Review of Neurobiology, 2020, 154, 235-278.	2.0	12

#	Article	IF	Citations
1170	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. Journal of Alzheimer's Disease, 2020, 77, 733-744.	2.6	7
1171	Blood Lipids and Cognitive Performance of Aging Polish Adults: A Case-Control Study Based on the PolSenior Project. Frontiers in Aging Neuroscience, 2020, 12, 590546.	3.4	11
1172	Cholesterol and Alzheimer's Disease Risk: A Meta-Meta-Analysis. Brain Sciences, 2020, 10, 386.	2.3	72
1173	Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain. Advances in Nutrition, 2020, 11, 1686-1695.	6.4	1
1174	Influence of Western diet and APOE genotype on Alzheimer's disease risk. Neurobiology of Disease, 2020, 138, 104790.	4.4	15
1175	High-Cholesterol Diet Decreases the Level of Phosphatidylinositol 4,5-Bisphosphate by Enhancing the Expression of Phospholipase C (PLCβ1) in Rat Brain. International Journal of Molecular Sciences, 2020, 21, 1161.	4.1	6
1176	Statin use and dementia after a concussion in older adults. Journal of the Neurological Sciences, 2020, 410, 116672.	0.6	0
1177	Effect of Combined Antihypertensive and Lipid-Lowering Therapies on Cognitive Function: A New Treatment Strategy?. Cardiology Research and Practice, 2020, 2020, 1-10.	1.1	11
1178	The Cognitive Effects of Statins are Modified by Age. Scientific Reports, 2020, 10, 6187.	3.3	20
1179	Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury. Alzheimer's Research and Therapy, 2020, 12, 33.	6.2	15
1180	Cholesterol homeostasis: Researching a dialogue between the brain and peripheral tissues. Pharmacological Research, 2021, 163, 105215.	7.1	50
1181	Cholesterol-lowering drugs reduce APP processing to $A\hat{l}^2$ by inducing APP dimerization. Molecular Biology of the Cell, 2021, 32, 247-259.	2.1	32
1182	Recent approaches to target apoptosis in neurological disorders. , 2021, , 217-283.		1
1183	Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets. Molecular Neurobiology, 2021, 58, 2183-2201.	4.0	93
1184	Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100012.	3.6	7
1185	Mitochondriaâ€associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease. Synapse, 2021, 75, e22196.	1.2	8
1186	The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders. Molecules, 2021, 26, 2838.	3.8	16
1187	Cholesterol and Alzheimer's Disease; From Risk Genes to Pathological Effects. Frontiers in Aging	3.4	110

#	Article	IF	CITATIONS
1188	Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood. Frontiers in Pharmacology, 2021, 12, 700587.	3.5	11
1189	Vascular Dementia and Cognitive Impairment. , 2022, , 221-236.e8.		1
1190	Sex and APOE genotype differences related to statin use in the aging population. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12156.	3.7	6
1191	Possible Relationship Between Statin Use and Decreased Incidence of Dementia: Are We Ready for a New Indication for These Drugs?. Archives of Internal Medicine, 2001, 161, 1909-1910.	3.8	4
1192	Statin-Alzheimer Disease Association Not Yet Proven. Archives of Neurology, 2001, 58, 1022-a-1023.	4.5	5
1193	Statin Therapy and the Prevention of Dementia. Archives of Neurology, 2001, 58, 1023-1024.	4.5	7
1194	Report on Statins and Dementia Disputed. Archives of Neurology, 2001, 58, 1166-1167.	4.5	6
1195	Statins and Dementia. Archives of Neurology, 2001, 58, 1169-1170.	4.5	15
1196	Apolipoprotein E: A Novel Therapeutic Target for the Treatment of Alzheimer's Disease. Advances in Behavioral Biology, 2002, , 39-43.	0.2	6
1197	Cholesterol—A Janus-Faced Molecule in the Central Nervous System. , 2007, , 151-170.		2
1198	Cholesterol and β-Amyloid. , 2007, , 93-111.		1
1199	Overview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets. , 2007, , 1-27.		7
1200	Central Nervous System Inflammation and Cholesterol Metabolism Alterations in the Pathogenesis of Alzheimer's Disease and Their Diagnostic and Therapeutic Implications. , 2009, , 125-137.		1
1201	Cholesterol and Hydroxycholesterol in the Brain. , 2011, , 267-297.		1
1202	Neuroprotective Strategies in Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2003, 513, 475-496.	1.6	8
1203	Dietary Fatty Acids and Cognitive Function. , 2002, , 31-46.		3
1204	Statins and Age-Related Maculopathy. , 2007, , 185-196.		1
1205	The Al²centric Pathway of Alzheimer's Disease. , 2007, , 5-36.		1

#	Article	IF	CITATIONS
1206	Cholesterol and Alzheimer's Disease. , 2007, , 142-158.		1
1207	Vascular Cognitive Impairment and Alzheimer Disease: Are These Disorders Linked to Hypertension and Other Cardiovascular Risk Factors?. , 2016, , 261-284.		2
1208	Lipoprotein Genes and Diet in the Evolution of Human Intelligence and Longevity. , 2003, , 33-67.		3
1209	Neuroinflammation in Alzheimer's Disease: Potential Targets for Disease-Modifying Drugs. , 2002, , 159-178.		1
1210	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. , 2020, , 469-504.		5
1211	Amyloid β-peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. Journal of Lipid Research, 2001, 42, 1292-1297.	4.2	87
1212	Oxidized cholesterol species as signaling molecules in the brain: diabetes and Alzheimer's disease. Neuronal Signaling, 2019, 3, NS20190068.	3.2	8
1213	What's New in Alzheimer's Disease?. Home Healthcare Nurse, 2003, 21, 8-14.	0.3	6
1214	Treatment of Patients with Lipid Disorders in the Primary Care Setting: New Treatment Guidelines and their Implications. Southern Medical Journal, 2003, 96, 266-275.	0.7	5
1215	Treatments for Alzheimer Disease. Southern Medical Journal, 2005, 98, 628-635.	0.7	25
1216	Cognitive Function and Antihypertensive Treatment in the Elderly: A 6-Year Follow-up Study. American Journal of Therapeutics, 2010, 17, 358-364.	0.9	24
1218	Detangling Alzheimer's Disease. Science of Aging Knowledge Environment: SAGE KE, 2003, 2003, 20a-2.	0.8	6
1220	Malformation syndromes due to inborn errors of cholesterol synthesis. Journal of Clinical Investigation, 2002, 110, 715-724.	8.2	88
1221	Cholesterol, lipid rafts, and disease. Journal of Clinical Investigation, 2002, 110, 597-603.	8.2	808
1222	Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation, 2002, 110, 285-288.	8.2	327
1223	Spotlight on BACE: The secretases as targets for treatment in Alzheimer disease. Journal of Clinical Investigation, 2001, 108, 1243-1246.	8.2	31
1224	Malformation syndromes due to inborn errors of cholesterol synthesis. Journal of Clinical Investigation, 2002, 110, 715-724.	8.2	43
1225	Cholesterol, lipid rafts, and disease. Journal of Clinical Investigation, 2002, 110, 597-603.	8.2	468

#	Article	IF	CITATIONS
1226	Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation, 2002, 110, 285-288.	8.2	210
1227	Alzheimer disease therapy: Can the amyloid cascade be halted?. Journal of Clinical Investigation, 2003, 111, 11-18.	8.2	125
1228	Liver X receptors and cholesterol metabolism: role in ventral midbrain development and neurodegeneration. F1000prime Reports, 2015, 7, 37.	5.9	15
1229	Amyloid-β Peptide on Sialyl-LewisX-Selectin-Mediated Membrane Tether Mechanics at the Cerebral Endothelial Cell Surface. PLoS ONE, 2013, 8, e60972.	2.5	10
1230	Chronic Pravastatin but Not Atorvastatin Treatment Impairs Cognitive Function in Two Rodent Models of Learning and Memory. PLoS ONE, 2013, 8, e75467.	2.5	45
1231	Statin Use and Cognitive Function: Population-Based Observational Study with Long-Term Follow-Up. PLoS ONE, 2014, 9, e115755.	2.5	13
1232	Statins Reduces the Risk of Dementia in Patients with Late-Onset Depression: A Retrospective Cohort Study. PLoS ONE, 2015, 10, e0137914.	2.5	14
1233	Mitochondrial cholesterol in health and disease. Histology and Histopathology, 2009, 24, 117-32.	0.7	79
1234	Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. Journal of Clinical Medicine Research, 2017, 9, 638-649.	1.2	17
1235	Lipidomics and cognitive dysfunction – A Narrative review. Turkish Journal of Biochemistry, 2020, 45, 109-119.	0.5	2
1236	Neuroprotective Effect of Rosuvastatin on Ca1 & Ca3 Regions of Hippocampus in High Fat Diet and Stress Induced Rats. International Journal of Neurology and Brain Disorders, 2014, 1, 1-5.	0.0	3
1237	Cholesterol Homeostasis Imbalance and Brain Functioning: Neurological Disorders and Behavioral Consequences. Journal of Neurology and Neurological Disorders, 2014, 1, .	0.0	5
1238	ls it possible to prevent dementia?. Revista Brasileira De Psiquiatria, 2002, 24, 22-27.	1.7	8
1240	Diabetes and Alzheimer's Disease - Is There a Connection?. Review of Diabetic Studies, 2006, 3, 161-161.	1.3	19
1241	Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis. Annals of Translational Medicine, 2018, 6, 435-435.	1.7	14
1242	Ongoing clinical trials of the pleiotropic effects of statins. Vascular Health and Risk Management, 2005, 1, 29-40.	2.3	41
1243	Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline. Current Medicinal Chemistry, 2014, 21, 2788-2802.	2.4	48
1244	Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases. Current Drug Metabolism, 2011, 12, 742-749.	1.2	65

#	Article	IF	CITATIONS
1245	The Complex Actions of Statins in Brain and their Relevance for Alzheimer's Disease Treatment: an Analytical Review. Current Alzheimer Research, 2014, 11, 1-1.	1.4	24
1246	The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 198-205.	1.4	35
1247	ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 699-709.	1.4	5
1248	Network Pharmacology: Exploring the Resources and Methodologies. Current Topics in Medicinal Chemistry, 2018, 18, 949-964.	2.1	51
1249	Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies. Current Diabetes Reviews, 2013, 9, 218-227.	1.3	60
1250	Impact of the CD40-CD40L Dyad in Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 149-155.	1.4	33
1251	Apolipoprotein E and cholesterol in aging and disease in the brain. Future Lipidology, 2008, 3, 505-530.	0.5	140
1252	Atorvastatin reduces the expression of aldo-keto reductases in HUVEC and PTEC. A new approach to influence the polyol pathway. Clinical and Investigative Medicine, 2009, 32, 219.	0.6	10
1253	Adverse effects of statin therapy: real evidence. Cardiosomatics, 2019, 10, 51-61.	0.4	4
1256	Therapeutic approaches to age-associated neurocognitive disorders. Dialogues in Clinical Neuroscience, 2001, 3, 191-213.	3.7	7
1257	Treatment of cognitive impairment in Alzheimer's disease. Dialogues in Clinical Neuroscience, 2003, 5, 35-43.	3.7	13
1258	Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?. Dialogues in Clinical Neuroscience, 2003, 5, 7-15.	3.7	14
1259	Is dementia preventable?. Dialogues in Clinical Neuroscience, 2009, 11, 213-216.	3.7	9
1260	Alzheimer's disease: How does it start?. Journal of Alzheimer's Disease, 2002, 4, 497-512.	2.6	88
1261	Pleiotropic effects of statins in the diseases of the liver. World Journal of Gastroenterology, 2016, 22, 6201.	3.3	42
1262	Does this patient have Alzheimer disease? Diagnosing and treating dementia Cleveland Clinic Journal of Medicine, 2003, 70, 762-762.	1.3	3
1263	Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleveland Clinic Journal of Medicine, 2008, 75, S87-S87.	1.3	16
1264	Effects of Hydrocortisone on the Pharmacokinetics of Loratadine after Oral and Intravenous Loratadine Administration to Rats. Biomolecules and Therapeutics, 2009, 17, 205-210.	2.4	3

~			<b>_</b>	
C	ITA'	τιον	IKF	PORT
$\sim$	11/1			

#	Article	IF	CITATIONS
1265	Changing the Course of Alzheimer's Disease. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 32-41.	0.6	31
1266	Neuroprotective effects of statins against amyloid β-induced neurotoxicity. Neural Regeneration Research, 2018, 13, 198.	3.0	31
1267	High Fibre Diets and Alzheimer's Disease. Food and Nutrition Sciences (Print), 2014, 05, 410-424.	0.4	20
1268	Linking multiple pathogenic pathways in Alzheimer's disease. World Journal of Psychiatry, 2016, 6, 208.	2.7	19
1269	The Prevalence of Alzheimer's Disease; its Risk and Protective Factors Among the Elderly Population in Iran. Shiraz E Medical Journal, 2017, 18, .	0.3	11
1270	Cholesterol and Alzheimer's disease. Neurology, 2002, 59, 150-151.	1.1	0
1271	Psychiatrische Erkrankungen. , 2003, , 1265-1384.		0
1273	Greasing Aging's Downward Slide. Science of Aging Knowledge Environment: SAGE KE, 2003, 2003, 6ns-6.	0.8	0
1274	The Principle Syndromes of Dementia. , 2004, , 1216-1233.		0
1275	Cognitive Disorders and Dementia. , 2005, , 201-217.		0
1276	Stroke Prevention, Blood Cholesterol and Statins. Neurological Disease and Therapy, 2005, , 123-150.	0.0	0
1278	Therapeutic Approaches to Modulation of Cell Death (non-HIV). , 2005, , 475-504.		0
1280	The Role of Sex Steroids in Alzheimer's Disease: Prevention and Treatment. , 2007, , 295-306.		0
1282	Interpreting Clinical Studies of Putative Therapeutics for Alzheimer's Disease: The Case of Statins and NSAIDs. , 2007, , 296-308.		0
1283	Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiological Research, 2007, 56, 765-770.	0.9	39
1284	3. èªçŸ¥ç—‡ã®ä≌´é~²ãëé€²è¡Œã®æŠʿå^¶. Japanese Journal of Clinical Pharmacology and Therapeutics, 2007, 38, 18	890105.	0
1285	Secretases as Pharmacological Targets in Alzheimer's Disease. , 2007, , 113-124.		1
1286	Neuroprotection for Acute Spinal Cord Injury - Comparison of Simvastatin and Atorvastatin The Journal of the Korean Orthopaedic Association, 2008, 43, 551.	0.1	0

		CITATION REF	PORT	
# 1287	ARTICLE Cerebral and Cardiac Vascular Pathology in Alzheimer's Disease. , 2009, , 159-169.		IF	CITATIONS
1288	HMGCoA-Reductase Inhibitors in Dementia: Benefit or Harm. Clinical Medicine Insights:	Geriatrics, 0, 3,	0.0	0
1289	Efectos no hipolipemiantes de las estatinas. Acta Medica Costarricense, 2008, 49, .		0.1	1
1290	Observational studies. , 2010, , 113-141.			0
1291	Angiogenic Mediators and the Pathogenesis of Alzheimerâ $\in$ Ms Disease. , 2010, , 295-3.	.2.		0
1292	The Search for Biomarkers in Alzheimer's Disease. Indonesian Biomedical Journal, 2010,	2, 4.	0.3	0
1293	Vascular Cognitive Impairment and Alzheimer Disease: Are These Disorders Linked to Hy Other Cardiovascular Risk Factors?. , 2011, , 195-210.	pertension and		0
1295	The Functions of the Amyloid Precursor Protein Gene and Its Derivative Peptides: III Pha Studies. Neuroscience and Medicine, 2011, 02, 397-409.	macological	0.2	0
1296	Pharmacoepidemiological Studies Using the Veterans Affairs Decision Support System.	0, , .		0
1298	Alzheimer-Demenz und weitere neurodegenerative Erkrankungen. , 2012, , 267-279.			0
1300	Alzheimer's Disease: Approaches to Pathogenesis in the Genomic Age. , 0, , .			0
1301	Therapeutic Opportunities in Alzheimer Disease: Current Concepts. , 2012, , 767-788.			0
1302	Rational of Current Practice of Prescribing Statin to Treat Dyslipidaemia as Primary Prev Coronary Heart Disease in Elderly People. Ibrahim Cardiac Medical Journal, 2011, 1, 45-5	ention of 5.	0.1	0
1303	Observational Studies. , 2016, , 109-136.			0
1305	Controversies over Statins-related Cognitive Impairment. International Journal of Cardio and Cerebrovascular Disease, 2016, 4, 20-25.	vascular	0.1	0
1306	Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therap Clinical Medicine Research, 2020, 12, 255-265.	y. Journal of	1.2	9
1307	Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players. Fror Neuroscience, 2021, 13, 766587.	tiers in Aging	3.4	13
1308	Demenzerkrankungen. , 2005, , 1395-1402.			0

#	Article	IF	CITATIONS
1309	Cholesterol Transport and Production in Alzheimerâ $\in$ <sup>Ms</sup> Disease. , 2008, , 211-219.		1
1310	Cholesterol and Aî $^2$ Production: Methods for Analysis of Altered Cholesterol De Novo Synthesis. , 2008, , 221-230.		0
1311	Alzheimer disease therapy: Can the amyloid cascade be halted?. Journal of Clinical Investigation, 2003, 111, 11-18.	8.2	57
1312	Mouse Models of Alzheimer's Disease. , 2007, , 259-273.		0
1313	Demenzerkrankungen. , 2007, , 1572-1580.		0
1314	Neurobiologie psychischer StĶrungen. , 2008, , 233-340.		0
1315	Biomarkers of Alzheimer disease in plasma. Neurotherapeutics, 2004, 1, 226-234.	4.4	0
1316	Statins and the prevention of dementia. Cmaj, 2001, 165, 908-9.	2.0	6
1317	Diet and Alzheimer's disease: what the evidence shows. MedGenMed: Medscape General Medicine, 2004, 6, 48.	0.2	6
1322	Brain microvasculature and hypoxia-related proteins in Alzheimer's disease. International Journal of Clinical and Experimental Pathology, 2011, 4, 616-27.	0.5	29
1323	The Association between Sporadic Alzheimer's Disease and the Human ABCA1 and APOE Gene Polymorphisms in Iranian Population. Iranian Red Crescent Medical Journal, 2011, 13, 256-62.	0.5	6
1328	CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY. Cognitive Sciences, 2010, 5, 35-56.	0.0	5
1330	The Black Book of Psychotropic Dosing and Monitoring. Psychopharmacology Bulletin, 2018, 48, 64-153.	0.0	1
1331	Favorable effects of dill tablets and L. extract on learning, memory, and hippocampal fatty acid composition in hypercholesterolemic rats. Iranian Journal of Basic Medical Sciences, 2021, 24, 300-311.	1.0	3
1332	An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia. Expert Review of Neurotherapeutics, 2021, 21, 1455-1472.	2.8	3
1333	Protective effect of olive leaves phenolic compounds against neurodegenerative disorders: Promising alternative for Alzheimer and Parkinson diseases modulation. Food and Chemical Toxicology, 2022, 159, 112752.	3.6	14
1334	Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism. Clinical Nutrition, 2022, 41, 698-708.	5.0	21
1335	Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology, 2022, 919, 174800.	3.5	7

#	Article	IF	CITATIONS
1337	The Role of Lipid Rafts and Membrane Androgen Receptors in Androgen's Neurotoxic Effects. Journal of the Endocrine Society, 2022, 6, bvac030.	0.2	5
1339	Molecular targets of statins and their potential side effects: Not all the glitter is gold. European Journal of Pharmacology, 2022, 922, 174906.	3.5	15
1340	Altered Cholesterol Homeostasis in Huntington's Disease. Frontiers in Aging Neuroscience, 2022, 14, 797220.	3.4	22
1341	Cyclodextrins as promising therapeutics against cholesterol overload. , 2022, , 927-967.		1
1342	Alzheimer's Disease: A Washing Machine on the Fritz. Journal of Behavioral and Brain Science, 2022, 12, 131-163.	0.5	1
1343	Therapeutic Targeting of Rab GTPases: Relevance for Alzheimer's Disease. Biomedicines, 2022, 10, 1141.	3.2	9
1344	Cholesterol and Dementia: A Possible Therapeutic Approach. , 2022, , 357-385.		0
1346	Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer's disease. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	21
1347	Statin contribution to middle cerebral artery blood flow velocity in older adults at risk for dementia. European Journal of Applied Physiology, 2022, 122, 2417-2426.	2.5	2
1348	Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease. Current Molecular Pharmacology, 2022, 15, .	1.5	0
1349	Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	6.2	6
1350	<i>In Vivo</i> Prenylomic Profiling in the Brain of a Transgenic Mouse Model of Alzheimer's Disease Reveals Increased Prenylation of a Key Set of Proteins. ACS Chemical Biology, 2022, 17, 2863-2876.	3.4	5
1351	Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment. CNS and Neurological Disorders - Drug Targets, 2022, 22, .	1.4	0
1353	Alzheimer's Disease: An Analysis of Gender Effects. Journal of Behavioral and Brain Science, 2022, 12, 455-473.	0.5	1
1354	Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated Review. Molecules, 2022, 27, 7207.	3.8	7
1356	The role of statins in clinical medicine -LDL - cholesterol lowering and beyond. Swiss Medical Weekly, 0, , .	1.6	11
1357	ALZHEIMER'S DISEASE AND VASCULAR FACTORS: FACTS AND THEORIES. International Journal of Clinical Practice, 2002, 56, 197-203.	1.7	10
1358	Cholesterol twists the transmembrane Di-Gly region of amyloid-precursor protein. , 2023, 2, .		0
#	Article	IF	CITATIONS
------	--	-----	-----------
1359	THE ASSOCIATION BETWEEN BLOOD COAGULATION MARKERS, ATHEROTHROMBOSIS AND DEMENTIA. International Journal of Clinical Practice, 2003, 57, 107-111.	1.7	7
1360	STATIN THERAPY: RATIONALE FOR A NEW AGENT, ROSUVASTATIN. International Journal of Clinical Practice, 2002, 56, 379-387.	1.7	2
1361	Fundamental neurochemistry review: Old brain stories ―Influence of age and sex on the neurodegenerationâ€associated lipid changes. Journal of Neurochemistry, 2023, 166, 427-452.	3.9	1
1362	Effect of the Lipid Landscape on the Efficacy of Cell-Penetrating Peptides. Cells, 2023, 12, 1700.	4.1	4
1363	Cognitive Enhancers and Treatments for Alzheimer's Disease. , 2023, , 1-42.		0
1364	Statins suppress cell-to-cell propagation of $\hat{i}\pm$ -synuclein by lowering cholesterol. Cell Death and Disease, 2023, 14, .	6.3	1
1365	Reexamining the Causes and Effects of Cholesterol Deposition in the Brains of Patients with Alzheimer's Disease. Molecular Neurobiology, 0, , .	4.0	0
1366	Neuronal γ-secretase regulates lipid metabolism, linking cholesterol to synaptic dysfunction in Alzheimer's disease. Neuron, 2023, 111, 3176-3194.e7.	8.1	5
1367	Acute Myocardial Infarction and Risk of Cognitive Impairment and Dementia: A Review. Biology, 2023, 12, 1154.	2.8	1
1368	Protective Effects of Statins against Alzheimer Disease. The Ewha Medical Journal, 2023, 46, .	0.2	0
1369	Protective Effects Against Dementia Undergo Different Statin Type, Intensity, and Cumulative Dose in Older Adult Type 2 Diabetes Mellitus Patients. Journal of the American Medical Directors Association, 2024, 25, 470-479.e1.	2.5	0

CITATION REPORT